



(11) **EP 1 407 269 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent:  
**20.10.2010 Bulletin 2010/42**

(21) Application number: **02754716.5**

(22) Date of filing: **20.06.2002**

(51) Int Cl.:  
**G01N 33/564 (2006.01)**

(86) International application number:  
**PCT/EP2002/006820**

(87) International publication number:  
**WO 2003/001212 (03.01.2003 Gazette 2003/01)**

(54) **A METHOD FOR DIAGNOSING A PERSON HAVING MULTIPLE SCLEROSIS**

VERFAHREN ZUR DIAGNOSE EINER PERSON MIT MULTIPLER SKLEROSE

METHODE DE DIAGNOSTIC D'UNE SCLEROSE EN PLAQUES CHEZ UNE PERSONNE

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR**  
Designated Extension States:  
**AL LT LV MK RO SI**

(30) Priority: **22.06.2001 US 299765 P**

(43) Date of publication of application:  
**14.04.2004 Bulletin 2004/16**

(73) Proprietors:  
• **Jansen, Burkhard**  
**1080 Wien (AT)**  
• **Lucas, Trevor**  
**1160 Wien (AT)**

(72) Inventors:  
• **Jansen, Burkhard**  
**1080 Wien (AT)**  
• **Lucas, Trevor**  
**1160 Wien (AT)**

(74) Representative: **Sonn & Partner Patentanwälte**  
**Riemergasse 14**  
**1010 Wien (AT)**

(56) References cited:  
**WO-A-01/02860 US-A- 5 158 893**  
**US-A- 5 883 227**

- **DATABASE EMBL [Online] Hypothetical protein, 28 March 2000 (2000-03-28) retrieved from EBI Database accession no. AJ276469, Q9NY07 XP002227576**
- **DATABASE EMBL [Online] Uncharacterized hypothalamus protein HSMNP1, 29 September 2000 (2000-09-29) retrieved from EBI Database accession no. AK026642 XP002227577**
- **DATABASE EMBL [Online] Uncharacterized hypothalamus protein HSMNP1, 4 May 2000 (2000-05-04) retrieved from EBI Database accession no. AF220191, Q9NZ31 XP002227578**

**EP 1 407 269 B1**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**Description**

**[0001]** The invention relates to a method for diagnosing a person having multiple sclerosis (MS) or being at risk of developing MS.

**[0002]** Multiple sclerosis (MS) is a common demyelinating disease of the central nervous system (CNS) affecting up to 0.1% of the north European caucasian population and is considered an auto-immune syndrome directed against unidentified central nervous tissue antigens. The determination of susceptibility to MS development is complex and governed by both environmental and genetic factors (Ebers et al, 1995; Sawcer and Goodfellow, 1998; Sadovnick et al, 2000) with approximately 20% of patients having one or more affected relatives (Chataway et al, 1998). Although thought to be a polygenetic disease, candidate gene approaches have been adopted to isolate genes linked to MS (Weinshenker and Kantarci, 2000). Association with the caucasian haplotype DRB\*1501-DQA1\*0102-DQB1\*0602 (Haines et al, 1998) and a point mutation in the protein tyrosine phosphatase receptor-type C (Jacobsen et al, 2000) have been linked to some cases. Recently, the importance of apoptosis in both T cell elimination and damage to neurons and oligodendrocytes in MS have been recognised (reviewed in Zipp, 2000).

**[0003]** However, to date no clear marker has been reported, although at least a portion of MS cases are clearly familial inherited. A mere recognition of MS or even providing a risk association would be very beneficial for early onset of therapy or preventive measures.

**[0004]** It is therefore an object of the present invention to provide an efficient diagnosis system for MS giving a clear indication and a clear correlation to this disease.

**[0005]** The subject matter of the invention is therefore a method for diagnosing a person having multiple sclerosis (MS) or being at risk of developing MS, characterised by the following steps:

- detecting the presence or absence of wild type SCF-Apoptosis-Response Gene- (wt-SARG-1-) protein and/or nucleic acids encoding wt-SARG-1 in a sample of a body fluid or tissue from said person, and
- diagnosing MS or a risk of acquiring MS, if wt-SARG-1-protein or nucleic acids encoding wt-SARG-1 are not present in said sample or not diagnosing MS, or a risk of acquiring MS, if wt-SARG-1-protein or nucleic acids encoding wt-SARG-1 are present in said sample.

**[0006]** Surprisingly, SARG-1 protein turned out to be a very specific marker for MS. Persons having either mutated SARG-1 protein or not expressing any SARG-1 protein due to mutations in SARG-1, have a clearly enhanced risk of MS. Investigations on the immuno-histochemical localisation of SARG-1 protein indicated that this protein is located in the grey and white matter of the CNS. The role of SARG-1 in apoptotic induction prompted a candidate gene approach to analyse the mutational status of SARG-1 in cases of familial MS. Indeed, DNA from 20 unrelated familial MS patients was examined by PCR amplification and DNA-sequencing of the SARG-1 locus and compared to SARG-1 sequences from healthy controls. It was found that all control samples demonstrated wild-type SARG-1 genomic sequences whereas in DNA from MS patients only 6 from 20 DNA samples were even able to be amplified by PCR, i.e. 14 from 20 did not show any detectable SARG-1 signals. In 4 of the 6 other patients genetic alterations were seen. A T → C point mutation at nucleotide 67 resulting in a substitution of phenylalanine with leucine at amino acid 23 (numbering of amino acids and nucleotides according to Figures 4-8); a C → T point mutation at nucleotide 359 resulting in the substitution of phenylalanine for serine at amino acid 120 (Fig.16), A → G point mutation a nucleotide 89 resulting in the substitution of glycine for glutamic acid at amino acid 30 (Fig. 17), deletion of a codon between amino acid 116 and 121 resulting in the loss of a serine residue (Fig. 18). Sequencing of only 20 control DNA samples revealed only wild-type sequence.

**[0007]** There is a number of restriction sites involved in these mutations: T → C at nucleotide 67 creates a number of restriction sites: Eco88I, XhoI, PaeR7I, Sfr274I, Ama781I, BcoI, BsoBI, Aval;

C → T at nucleotide 359 creates an additional BseRI restrictionsite.

**[0008]** Especially preferred samples according to the present invention are derived from human blood, plasma, serum, lymph, nerve-cell containing tissue, cerebrospinal fluid, all biopsy-material, including tumor tissue, bone marrow, nervous tissue, skin, hair, tears, fetal material including amniocentesis material, uterine tissue, saliva, faeces, sperm, etc.

**[0009]** In principle, any method for detecting the presence of wt-SARG-1 protein or nucleic acid encoding wt-SARG-1 in the sample may be applied according to the present invention. Preferably methods are applied which allow also a characterisation of specific SARG-1 mutants if present, either by giving the information that a mutant is present or by analysing the nature of the mutant form in detail.

**[0010]** Especially detecting the presence of point mutations may be preferred within the present invention, i.e. non-wt-forms of SARG-1 differing from wt-SARG-1 or wt-SARG-1 protein in one nucleic acid residue, or one amino acid residue, respectively. The method according to the present invention may be designed to identify those point mutations, especially point mutations leading to the different amino acid sequence, e.g. exchange of one amino acid residue from the wild type SARG-1 protein.

**[0011]** Suitable methods for detecting the presence of wt-SARG-1 protein or nucleic acids encoding are known in the

art, preferably nucleic acids encoding wt-SARG-1 are detected by nucleic acid amplification methods, especially polymerase chain reaction methods, single-strand conformation polymorphism (SSCP) analysis, restriction analysis, microarray technology, proteomics, etc. These methods have been shown as being fast, highly reliable and easily conductable on a high throughput basis. Those tests could be performed on standard tissue or body fluid samples, such as blood, hair or saliva.

**[0012]** On the other hand, preferred methods for detecting the presence of wt-SARG-1 protein encompass the application of a wt-SARG-1 protein antibody, especially a monoclonal antibody, e.g. in a ELISA-format. Such antibodies may be easily produced on an industrial scale with a high degree of standardisation potential.

**[0013]** The method according to the present invention is especially suited to be applied within a screening test format.

**[0014]** The SARG-1 intron/exon structure is given in Fig. 19. The transcription start site initiator consensus YYCARR is underlined. Donor (GU) and acceptor (AG) splice sites are underlined in italics; exons are in bold type. Coding exon sequences are in italic. SARG-1 is located on human chromosome 20q12-13.12.

**[0015]** A nucleic acid according to Seq. ID. No. 1 (Fig. 4) encoding human wild-type SARG-1 may be used for diagnosis but also for therapeutic aspects by providing therapeutic molecules or gene sequences for gene therapy aspects, e.g. by antisense strategies, design of small molecule drugs.

**[0016]** The present invention also encompasses nucleic acid molecules comprising a sequence according to Seq.ID.No.1, wherein one nucleic acid residue is exchanged wherein said exchange is selected from a T to C exchange at position 67 of Seq.ID.No.1, an A to G exchange at position 89 of Seq.ID.No.1 and a C to T exchange at position 359 of Seq.ID.No.1. These exchanges relate to exchanges already observed in MS patients. Further exchanges resulting in a viable phenotype are also preferred.

**[0017]** Other preferred mutations in the nucleic acid molecule according to the present invention comprises a deletion in the coding region, preferably a deletion of one or more codons (e.g. 3 nucleic acids, or 6, 9, 12, etc.). One of these mutations leads to the deletion of a codon between amino acids 116 and 121, resulting in the loss of a serine residue (Fig. 19). Mutations leading to non-functional SARG-1 on SARG-1 protein may also be located in the controlling regions (5' or 3') and/or in the sequences, especially at critical positions for correct splicing.

**[0018]** When the nucleic acid molecule according to the present invention is used for a diagnostic purpose, it is not necessary to use the whole sequence. For use as a probe or performing a method according to the present invention selectively binding to a fragment of the mutated form of Seq.ID.No.1 selected from the T to C exchange at position 67, the A to G exchange at position 89 or the C to T exchange at position 359, preferably having a length of at least 12, more preferred at least 15, especially at least 20, nucleic acid residues is suitable for performing various tests, especially diagnostic tests with these probes, e.g. as a probe to identify or isolate nucleic acid samples or even chromosomal samples or as PCR primers, etc.

**[0019]** The nucleic acid molecules are not restricted to the coding sequence according to Seq.ID.No.1, but also relate to the genomic counterparts including the whole exon/intron structure of this gene, especially also imitations in the non-coding region resulting in non-wild type forms of the protein (or non-translated forms of the protein) are encompassed by the present invention.

**[0020]** Described is also a polypeptide being encoded by this nucleic acid molecule, e.g. comprising an amino acid sequence according to Seq.ID.No. 2. There is single potential N-glycosylation site with consensus Asn-X-Ser/Thr (amino acid residues 131-133)

MDPNPRAALERQQLRLRERQKFFEDILQPETEFVFPPLSHLHLESQRPPIGSISSEMEVNVDTLE -  
QVELIDLGDPAADVFLPCEDPPPTPQSSGVDNHLEELSLPVPTSDRTTTSRTSSSSSSSDSSTNLHSPN -  
PSDDGADTPLAQSDDEEEERGDGGAEPGACS

**[0021]** All threonine and serine residues may be O-glycosylated. Computer predictions indicate high likelihood of glycosylation of serine residues 91, 108, 113, 117, 118, 119, 120, 121, 123, 124 and 133 and the threonine residues 88, 107, 111, 112, 115 and 125.

**[0022]** Similarly, all threonine and serine residues may be phosphorylated. Computer predictions indicate high likelihood of phosphorylation of serine residues 54, 92, 108, 113, 116, 117, 118, 119, 120, 121, 123, 124, 129, 133 and 144 and the threonine residues 61, 88, 107, 112 and 139.

**[0023]** No signal sequences, characteristic domains or other 3-dimensional structures have been detected other than potential protein kinase recognition sites. Of course, amino acid sequences having an amino acid residue exchange wherein the amino acid residue exchanges of the polypeptide are selected from amino acid residues Phe23, Glu30 and Ser120, especially Phe23 to Leu 23, Glu30 to Gly30 and Ser120 to Phe120 exchanges are also encompassed in the present invention.

**[0024]** Deletions of the SARG-1 gene may be partial or full to serve as marker. Diagnostic tests for screening for the

presence or absence of such a marker are easily conceivable and reduced to practice by the skilled man in the art.

**[0025]** Preferred polypeptides according to the present invention are recombinantly produced which exhibit structural differences compared to wt-SARG-1 protein, e.g. differential glycosylation, especially non-homogeneous glycosylation.

**[0026]** Also disclosed is a method for making an antibody preparation comprising administering a polypeptide according to the present invention to an animal, allowing said animal to generate antibodies against said polypeptide, extracting antibody-containing body fluids or tissue from said animal and preparing an antibody preparation against said polypeptide from said body fluids or tissue. This method is especially applicable for making polyclonal antibodies.

**[0027]** For making monoclonal antibodies a method for making such an antibody preparation is preferred, comprising administering a polypeptide according to the present invention to an animal, allowing said animal to generate antibodies against said polypeptide, removing the spleen of said animal, preparing fusion cells of said spleen cells with suitable hybridoma generating cells, generating hybridoma cells producing monoclonal antibodies against said polypeptide, cloning and culturing said hybridoma cells, thereby expressing monoclonal antibodies, and preparation of said monoclonal antibodies. The skilled man in the art thereby relies on methods readily available for such purposes and e.g. described in "Antibodies: A laboratory manual" by Ed Harlow, Cold Spring Harbor Laboratory; David Lane, Imperial Cancer Research Fund Laboratories, 1988. Of course, also phage display peptides may also easily be generated.

**[0028]** The present invention also relates to the use of a kit for performing the *in vitro* diagnosing method according to the present invention which comprises at least means for detecting the presence of wt-SARG-1 protein or nucleic acids encoding wt-SARG-1. The skilled man in the art can envisage the basis of the disclosure of the present application a wide number of suitable alternatives, e.g. anti-wt-SARG-1 protein antibodies, nucleic acid probes selectively binding to wt-SARG-1, nucleic acid primers defining a region being selective for a wt-SARG-1, a chip comprising said nucleic acid probes or said nucleic acid primers. Other preferred means or assays are assays in which proteins bind to SARG-1 such as antibodies or peptides including mutation specific antibodies, ELISAS, Western Blotting assays, flow cytometry assays and assays using immunohistochemical techniques including confocal microscopy.

**[0029]** Described is also a transgenic non-human animal model, especially an animal wherein the SARG-1 gene has been mutated or knocked out. A SARG-1 knock out mouse is especially preferred. Methods for providing such models, especially the mouse models, are readily available to the skilled man in the art. Such an animal model is extremely useful in studying genetic variations and mutations of SARG-1, especially with respect to its MS-related disorders.

**[0030]** The term "transgenic" is used herein to describe genetic material that has been or is about to be artificially inserted into the genome of a mammalian cell, particularly a mammalian cell of a living animal. The transgene is used to transform a cell, meaning that a permanent or transient genetic change, preferably a permanent genetic change, is induced in a cell following incorporation of exogenous DNA. A permanent genetic change is generally achieved by introduction of the DNA into the genome of the cell. Vectors for stable integration include plasmids, retroviruses and other animal viruses, YACs, and the like. Of interest are transgenic non-human mammals, e.g. cows, pigs, goats, horses, etc., and particularly rodents, e.g. rats, mice, etc.

**[0031]** Transgenic non-human animals comprise an exogenous nucleic acid sequence present as an extrachromosomal element or stably integrated in all or a portion of its cells, especially in germ cells. Unless otherwise indicated, it will be assumed that a transgenic non-human animal comprises stable changes to the germline sequence. During the initial construction of the animal, "chimeras" or "chimeric animals" are generated, in which only a subset of cells have the altered genome. Chimeras are primarily used for breeding purposes in order to generate the desired transgenic animal. Animals having a heterozygous alteration are generated by breeding of chimeras. Male and female heterozygotes are typically bred to generate homozygous animals.

**[0032]** Transgenic non-human animals fall into two groups, colloquially termed "knockouts" and "knockins". In the present invention, knockouts have a partial or complete loss of function in one or both alleles of the endogenous SARG-1. Knockins have an introduced transgene with altered genetic sequence and function from the endogenous gene. The two may be combined, such that the naturally occurring gene is disabled, and an altered form introduced.

**[0033]** In a knockout, preferably the target gene expression is undetectable or insignificant. A knock-out of a SARG-1 means that function of the SARG-1 protein has been substantially decreased so that expression is not detectable or only present at insignificant levels or mutated according to the teachings according to the present invention to perform as suitable model for the situation in humans as described herein. This may be achieved by a variety of mechanisms, including introduction of a mutation or disruption of the coding sequence, e.g. insertion of one or more stop codons, insertion of a DNA fragment, etc., deletion of coding sequence, substitution of stop codons for coding sequence, etc. In some cases the exogenous transgene sequences are ultimately deleted from the genome, leaving a net change to the native sequence. Different approaches may be used to achieve the "knock-out". A chromosomal deletion of all or part of the native gene may be induced, including deletions of the non-coding regions, particularly the promoter region, 3' regulatory sequences, enhancers, or deletions of genes that activate expression of SARG-1. A functional knock-out may also be achieved by the introduction of an anti-sense construct that blocks expression of the native genes (for example, see Li and Cohen (1996) Cell 85:319-329). "Knock-outs" also include conditional knock-outs, for example where alteration of the target gene occurs upon exposure of the animal to a substance that promotes target gene alteration, introduction

of an enzyme that promotes recombination at the target gene site (e.g. Cre in the Cre-lox system), or other method for directing the target gene alteration postnatally.

**[0034]** A "knock-in" of a target gene means an alteration in a host cell genome that results in altered expression or function of the native SARG-1. Increased (including ectopic) or decreased expression may be achieved by introduction of an additional copy of the target gene, or by operatively inserting a regulatory sequence that provides for enhanced expression of an endogenous copy of the target gene. These changes may be constitutive or conditional, i.e. dependent on the presence of an activator or represser.

**[0035]** The exogenous gene is usually either from a different species than the animal host, or is otherwise altered in its coding or non-coding sequence. The introduced gene may be a wild-type gene, naturally occurring polymorphism or mutation, or a genetically manipulated sequence, for example having deletions, substitutions or insertions in the coding or non-coding regions. The introduced sequence may encode wild-type human or animal SARG-1 protein or a mutation thereof, or may utilize the SARG-1 promoter operably linked to a reporter gene. Where the introduced gene is a coding sequence, it is usually operably linked to a promoter, which may be constitutive or inducible, and other regulatory sequences required for expression in the host animal. By "operably linked" is meant that a DNA sequence and a regulatory sequence(s) are connected in such a way as to permit gene expression when the appropriate molecules, e.g. transcriptional activator proteins, are bound to the regulatory sequence(s).

**[0036]** Specific constructs of interest, include, but are not limited to anti-sense SARG-1, which will block native SARG-1 expression, expression of dominant negative SARG-1 mutations, and over-expression of a SARG-1. A detectable marker, such as lac Z may be introduced into the locus, where upregulation of expression will result in an easily detected change in phenotype. Constructs utilizing the SARG-1 promoter region, in combination with a reporter gene or with the coding region are also of interest.

**[0037]** A series of small deletions and/or substitutions may be made in the SARG-1 to determine the role of different exons in DNA binding, transcriptional regulation, etc. By providing expression of SARG-1 protein in cells in which it is otherwise not normally produced, one can induce changes in cell behavior.

**[0038]** DNA constructs for homologous recombination will comprise at least a portion of the SARG-1 with the desired genetic modification, and will include regions of homology to the target locus. DNA constructs for random integration need not include regions of homology to mediate recombination. Conveniently, markers for positive and negative selection are included. Methods for generating cells having targeted gene modifications through homologous recombination are known in the art. For various techniques for transfecting mammalian cells, see Keown et al. (1990) *Methods in Enzymology* 185:527-537.

**[0039]** For non-human embryonic stem (ES) cells, an ES cell line may be employed, or embryonic cells may be obtained freshly from a non-human host, e.g. mouse, rat, guinea pig, etc. Such cells are grown on an appropriate fibroblast-feeder layer or grown in the presence of appropriate growth factors, such as leukemia inhibiting factor (LIF). When ES cells have been transformed, they may be used to produce transgenic non-human animals. After transformation, the cells are plated onto a feeder layer in an appropriate medium. Cells containing the construct may be detected by employing a selective medium. After sufficient time for colonies to grow, they are picked and analyzed for the occurrence of homologous recombination or integration of the construct. Those colonies that are positive may then be used for embryo manipulation and blastocyst injection. Blastocysts are obtained from 4 to 6 week old superovulated females. The ES cells are trypsinized, and the modified cells are injected into the blastocoel of the blastocyst. After injection, the blastocysts are returned to each uterine horn of pseudopregnant females. Females are then allowed to go to term and the resulting litters screened for mutant cells having the construct. By providing for a different phenotype of the blastocyst and the ES cells, chimeric progeny can be readily detected.

**[0040]** The chimeric non-human animals are screened for the presence of the modified gene and males and females having the modification are mated to produce homozygous progeny. If the gene alterations cause lethality at some point in development, tissues or organs can be maintained as allogeneic or congenic grafts or transplants, or in in vitro culture.

**[0041]** Binding partners of human SARG-1 include protein-O-mannosyltransferase 1 (POMT1), microtubule-associated protein 1 A (MAP1A),

ATPase, Na<sup>+</sup>/K<sup>+</sup> transporting beta 1 polypeptide (ATP1B1), SWI/SNF complex 60 KDa subunit (BAF60c) alpha-Actinin 2, exon 16, rab GDP dissociation inhibitor 1 (GDI1) and proteasome 26 S subunit, ATPase 3 (PSMC3).

**[0042]** It is also possible to use SARG-1 binding proteins for modulating activity of SARG-1 proteins (including mutants) and vice versa. Moreover, SARG-1 (wild type) or SARG-1 binding proteins may be used for treating MS by administering an effective amount of SARG-1 or SARG-1 binding protein (or a complex thereof) to an MS patient. Instead of wt-SARG-1 protein, also fragments of SARG-1 may be used which are suitable for advantageous treatment of such patient (e.g. fragments binding to the SARG-1 binding proteins). Minimum requirements for such fragments are easily found by the skilled man in the art especially using the mouse models described herein.

**[0043]** The method is further described by the examples and drawing figures, without being restricted thereto.

Fig. 1 shows reverse northern blot demonstrating induction of the rat SARG-1 gene during apoptosis. Plasmid DNA

## EP 1 407 269 B1

was spotted onto nylon membranes and hybridised with radiolabelled cDNA isolated from apoptotic stem cells. Plasmids containing the 5' region of SARG-1 (arrowed) hybridise with cDNA only present in apoptotic cells. Control cDNA from self-renewing cells showed only background levels (data not shown).

5 Fig. 2 shows rat multiple tissue northern blot. The 342bp SARG-1 fragment was radiolabelled and hybridised with RNA isolated from different rat tissues. A species of approximately 1.4Kb is observed with an ubiquitous tissue distribution and highest expression in brain and heart.

10 Fig. 3 shows mouse embryonic tissue northern blot. The 342bp SARG-1 fragment was radiolabelled and hybridised with RNA isolated from various stages of embryonic development. Clear regulation of a 1.4Kb species is seen with highest levels after 7 days and re-expression of the gene product on day 17.

Fig. 4 shows full length rat mouse and human SARG-1 cDNA sequences.

15 Fig. 5 shows comparisons between full length rat mouse and human SARG-1 cDNA sequences.

Fig. 6 shows full length rat, mouse and human SARG-1 coding sequences with corresponding predicted amino acid sequence.

20 Fig. 7 shows comparison between the rat, mouse and human SARG-1 DNA coding sequences.

Fig. 8 shows comparison between the rat, mouse and human SARG-1 amino acid coding sequences.

25 Fig. 9 shows immunohistochemical analysis of mouse tissue with anti-SARG-1 peptide antibodies. A brown reaction product indicates SARG-1 expression. A: Mouse cerebral cortex (magnification x40), B: Cerebellum (x40), C: Spinal chord (x40), D: Peripheral nerve (x60), E: Heart (x40) and F: Lung tissue (x40).

30 Fig. 10 shows SARG-1 protein detected by western blotting of cellular extracts from MelJUSO melanoma cells transfected with pMH-SARG-1-HA. Anti-HA monoclonal antibody 3F10 detected a single species which migrates at 28kD.

35 Fig. 11 shows immunohistochemical analysis of human SARG-1 protein in MELjuso cells transfected with pMH-SARG-1-HA detected by the anti-HA monoclonal antibody 3F10 demonstrating cytoplasmatic localisation of the protein.

Fig. 12 shows viability of PC12 cultures transfected with empty vector or pIRES2-EGFP-SARG-1 treated with 100nM staurosporine.

40 Fig. 13 shows flow cytometrical analysis of PC12 cells transfected with empty vector or pIRES2-EGFP-SARG-1 treated with 100nM staurosporine for 24h. A sub  $G_0/G_1$  peak characteristic for the induction of apoptosis is seen only in SARG-1 over-expressing cells.

45 Fig. 14 shows PC12 cells that overexpress SARG-1 protein (■) undergo accelerated NGF-mediated terminal differentiation when compared to cells transfected with empty vector (◆).

Fig. 15 shows genetic alteration in familial multiple sclerosis. A T → C point mutation at nucleotide 67 resulting in the substitution of leucine for phenylalanine amino acid 23.

50 Fig. 16 shows genetic alteration in familial multiple sclerosis. A C → T point mutation at nucleotide 359 resulting in the substitution of phenylalanine for serine at amino acid 120.

Fig. 17 shows genetic alteration in familial multiple sclerosis. An A → G point mutation at nucleotide 89 resulting in the substitution of glycine for glutamic acid at amino acid 30.

55 Fig. 18 shows genetic alteration in familial multiple sclerosis. Deletion of a codon between amino acids 116 and 121 resulting in the loss of a serine residue.

Fig. 19 shows the SARG-1 intron/exon structure.

**Examples:****Identification of a novel SCP-Apoptosis-Response-Gene (SARG-1) induced during stem cell apoptosis**

5 **[0044]** Withdrawal of growth factor from SCF dependent myelomonocytic progenitors results in rapid induction of cell cycle-independent apoptosis. Although over 95% of SCF-deprived cultures exclude vital dyes 12 hours after growth factor withdrawal, no proliferative response is seen on restimulation with SCF after this time point. A differential display screen was conducted to examine immediate-early (four hour) mRNA expression differences during the processes of myelomonocytic stem cell self-renewal and apoptosis induced by growth factor withdrawal. Amplification of approximately 10 1/3 of all cellular mRNA species by differential display PCR (Liang and Pardee 1992, 1995; Liang et al, 1993) with defined primer (Bauer et al, 1993) sets (Display systems) identified one fragment induced during apoptosis not present in self-renewing precursors. Following gel excision of this band and TA cloning into the pCR<sup>II</sup> vector (Invitrogen) of reamplificants, specific expression induction was confirmed in a reverse northern procedure with representative dot blotted plasmid preparations hybridised with radiolabelled cDNA isolated prepared from independent cultures (Fig. 1). All positively identified differentially regulated clones were sequenced and found to contain an identical 342 base pair insert (excluding the downstream and upstream differential display primer pairs). 15

**Molecular weight of SARG-1 cDNA and tissue expression. Regulation during embryonic development**

20 **[0045]** Radioactive labelling of the 342bp fragment discovered above and probing of multiple tissue northern blots (Clontech) showed an approximately 1300bp length for the mature mRNA in rat, mouse and human tissues. An ubiquitous low expression was seen with highest expression levels in brain and heart (Fig.2). Northern blots of immobilised mRNA isolated from different stages of murine embryonic development probed with the radioactively labelled 342bp fragment demonstrated regulation of SARG-1 mRNA during development with highest levels after 7 days and re-expression of the gene product on day 17 (Fig.3). 25

**Cloning of full length rat, murine and human SARG-1.**

30 **[0046]** Additional SARG-1 sequence information was obtained by a 5' rapid amplification of cDNA ends polymerase chain reaction (RACE) procedure from adapter ligated rat brain Marathon-ready cDNA (Clontech). A primer was constructed at the 3' proximal end of the 342bp sequence and the PCR product cloned into the pCR<sup>®</sup> TA cloning vector (Invitrogen) and sequenced. The full length SARG-1 1062bp gene transcript was sequenced and has a 479bp open reading frame which encodes a 158 amino acid protein. Murine SARG-1 was isolated by screening a bacterial artificial chromosome bank derived from mouse strain 129SvJ with the full length rat SARG-1 cDNA. Homologous clones were 35 isolated and a Xho I fragment sequenced. Mature murine SARG-1 RNA was then identified by PCR from mouse brain cDNA. Human SARG-1 was isolated from a phage bank of brain cDNA by homology to the full length rat sequence and sequenced. The full human SARG-1 locus was amplified by PCR with primers spanning the SARG-1 cDNA from chromosomal DNA isolated from the peripheral blood mononuclear cells of healthy volunteers. The full length sequences of rat, mouse and human SARG-1 are shown in Figs. 4, 5 and 6. 40

**The Homologies between rat, mouse and human sequences**

45 **[0047]** Rat and mouse SARG-1 are 93% at the nucleic acid and 96% homologous at the predicted protein levels, respectively. Human SARG-1 displays 83% and 84% homologies to mouse and rat SARG-1 at the nucleic acid level and 84% and 86% homologies at the predicted protein levels, respectively (Figs. 7 and 8), and is localised to the long arms of chromosome 20 (at 20q13.12 (Deloukas et al., 2001)), deletion of which are a common occurrence in a wide range of myeloproliferative disorders (Wattel et al, 1993 and Bench et al., 2000). Sequences contain a potential PEST region (Rechsteiner et al. 1996) (+), a single conserved potential N-glycosylation site (#) and three conservers PKC(§) and casein kinase II (\*) phosphorylation sites (see Fig. 5B). 50

**Analysis of SARG-1 distribution with anti-SARG-1 antibodies**

55 **[0048]** SARG-1 antibodies were prepared by immunising chickens with a peptides (MDPNPRAALERQQLR and DEEEERGDGGAEPGA) corresponding to the first 15 amino acids and to the c-terminal part of mouse, rat and human SARG-1 coupled to keyhole limpet hemocyanin. IgY was prepared from egg yolks and specific antibody prepared by affinity chromatography with column-immobilised peptide.

**[0049]** In immunohistochemical analysis of 5mm acetone-fixed sections of mouse tissue, specific anti-SARG-1 IgY antibodies visualised with anti-IgY peroxidase conjugated second step antibodies, detected wide expression of the

SARG-1 protein in nervous tissue. SARG-1 staining is seen throughout the cerebral cortex (Fig.9A) and within the granular, Purkinje and molecular cell layers of the cerebellum (Fig.9B). In the spinal chord, SARG-1 is expressed in both the gray matter neurophil containing nerve cell bodies, dendrites, glial cells and blood vessels and the white matter consisting largely of myelinated nerve tracts (Fig.9C). SARG-1 expression is also colocalised to occasional peripheral nerve processes (Fig.9D). SARG-1 is also ubiquitously expressed in cardiac muscle, (Fig.9E), lung ciliated epithelia (Fig.9F) and epithelial cells of the ileum and colon (data not shown). Staining of mouse embryonic tissue demonstrated strong staining of neural tissue, brain, heart, placenta, uterus, the organ of corti, the dermis (stratum granulosum) and lining of the gut (data not shown).

#### 10 **Generation of SARG-1 over-expressing cells**

**[0050]** The MeJUSO melanoma cell line was maintained in Dulbecco's modified eagles medium (DMEM) supplemented with 10% fetal calf serum and an antibiotic-antimycotic mix containing 100 units/ml penicillin, 100 µg/ml streptomycin, and 0.25 µg/ml amphotericin B (all from GibcoBRL) in a fully humidified air atmosphere containing 5% CO<sub>2</sub> at 37°C. The human SARG-1 coding sequence (hSARG-1<sub>486</sub>) was cloned into the pMH expression vector (Roche) by standard molecular biology procedures (Sanbrook et al, 1989) under the control of a CMV promoter in frame with a c-terminal hemagglutinin (HA) peptide sequence. Semi-confluent cultures in 6 well plates were transfected with this vector (pMH-SARG-1-HA) or empty vector in the presence of Fugene (Roche) and clones isolated which displayed resistance to neomycin.

**[0051]** To examine the expression and function of SARG-1 in a neural cell culture system, standard molecular biology techniques (Sanbrook et al, 1989) were used to clone the rat SARG-1 coding sequence (rSARG-1<sub>479</sub>) into the pIRESII-EGFP eukaryotic expression vector (Clontech) under the control of a CMV promoter which bicistronically translates through an internal IRES sequence both SARG-1<sub>477</sub> and enhanced green fluorescent protein. The rat pheochromocytoma PC12 cell line was maintained in DMEM supplemented with 8% horse serum, 8% fetal calf serum and an antibiotic-antimycotic mix containing 100 units/ml penicillin, 100 µg/ml streptomycin, and 0.25 µg/ml amphotericin B (all from GibcoBRL) in a fully humidified air atmosphere containing 5% CO<sub>2</sub> at 37°C. Semi-confluent cultures in 6-well plates were transfected with pIRES2-EGFP-SARG-1 or empty vector for 18 h in the presence of the uptake enhancing cationic lipid mix pF<sub>x</sub>1 (Invitrogen) at a 6:1 lipid to DNA ratio in serum-free Opti-MEM (Gibco). Stable transfectant colonies were picked from separate wells after selection in 800 mg/ml geneticin (Gibco) and clones with similar EGFP fluorescence expanded from independent transfections.

#### **Post translational modification of mature rat and human proteins**

**[0052]** The molecular weights of rat, mouse and human SARG-1 protein predicted from the amino acid sequences are 17186.52, 17193.52 and 17492.76, respectively. IgY antibodies against SARG-1 detect a 28kD species in western blotting expressed at low levels in native PC12 cells. Upon transfection of pIRES2-EGFP-SARG-1 into these cells, expression levels of this species increase. The molecular weight of human SARG-1 protein was determined by western blotting of cellular extracts from MeJUSO melanoma cells transfected with pMH-SARG-1-HA. Anti-HA monoclonal antibody 3F10 (Roche) detected a single species which migrates at 28kD (Fig. 10).

#### **Subcellular localisation of transfected SARG-1 protein**

**[0053]** Immunohistochemical staining of SARG-1 transfected PC12 cells demonstrated an exclusive cytoplasmic localisation for the SARG-1 gene product. Immunohistochemical analysis with anti-HA monoclonal antibody 3F10 also demonstrated an exclusive cytoplasmic localisation for the SARG-1 protein (Fig. 11) primarily colocalising with expression of binding protein (bip) used as marker for the endoplasmatic reticulum. Co-localisation of HA-SARG-1 with the golgi-specific antigen coat protein (b-cop) is minimal. In contrast, SARG-1 expression partly overlaps with expression of the lysosomal specific protein LAMP-2.

#### **Role of SARG-1 in apoptosis and differentiation of neural cell cultures**

**[0054]** Treatment of PC12 cells with the protein kinase inhibitor staurosporine induces neurite outgrowth at concentrations of 100nM (Hashimoto and Hagino, 1989) and apoptosis at concentrations above 1mM (Fu et al, 1999). SARG-1 over-expressing PC12 cells undergo a rapid loss in viability on treatment with 100nM staurosporine (Calbiochem) in comparison to vector control cultures (Fig.12) which undergo neurite outgrowth. Cell death in SARG-1 over-expressing PC12 cultures is accompanied by cell shrinkage, development of a morphology characteristic of programmed cell death and loss of DNA from ethanol fixed cells in flow cytometrical cell cycle analyses (Fig. 13) characteristic of the apoptotic process (Fraker et al, 1995). No similar effects are seen with the staurosporine analogue K252a (Alexis), the phosphati-

dylinositol 3-kinase inhibitors LY-294002 (Alexis) or Wortmannin (Calbiochem), the MAP kinase kinase inhibitor PD 98059 (Alexis) or the protein kinase C inhibitor Bisindolylmaleimide I (Alexis). Over-expression of SARG-1 also enhances terminal differentiation of PC12 cells induced by nerve growth factor (Fig. 14).

## 5 Isolation of SARG-1 binding proteins

**[0055]** Yeast two hybrid screening are performable with the commercially available Matchmaker system from Clontech. The bait plasmid is constructed by cloning the full length hSARG-1 coding sequence into the pGBKT7 shuttle vector (Clontech) by PCR using the BamH1 and EcoR1 restriction sites using standard methods (shuttle vector pGBKT7: The coding region of hSARG-1 is cloned as a c-terminal fusion to amino acids 1-147 of the GAL4 DNA binding domain (DNA-BD) containing a c-myc tag under the control of the yeast ADH1 promoter (P) by PCR amplification using the EcoR1 and BamH1 restriction sites and selected in yeast using the TRP1 nutritional marker). This construct is then used to lithium acetate transform the MATa yeast strain AH109 which is auxotrophic for adenine (Ade), histidine (His) leucine (Leu) and tryptophan (Trp) and selected for pGBKT7 by growth on synthetic dropout (SD)-Trp medium. A human brain matchmaker library (Clontech) directionally constructed in pACT2 pretransformed in the MAT $\alpha$  Y187 (Ade<sup>-</sup>, His<sup>-</sup> Leu<sup>-</sup> and Trp<sup>-</sup>) yeast strain is purchased and at least 3x10<sup>6</sup> clones mated with AH109 transformed hSARG-1-1 (shuttle vector pACT2: Human brain library inserts are directionally cloned in frame as c-terminal fusions to amino acids 768-881 of the GAL4 activation domain, the SV40 T-antigen nuclear localization sequence and a HA epitope tag under the control of the yeast ADH1 promoter (P) and selected in yeast using the LEU2 nutritional marker). Zygotes are isolated by Leu<sup>-</sup> and Trp<sup>-</sup> selection and protein interactions simultaneously by reporter gene activation of HIS3, ADE2, and MEL1 on -His, -Ade plates containing X- $\alpha$ -Gal (5-Bromo-4-chloro-3-indolyl-a-D-galactopyranoside), respectively. Positive colonies are restreaked and additionally tested for lacZ reporter activation with  $\beta$ -galactosidase. The inserts from positive colonies are amplified by PCR, repeats identified by restriction digestion and positive interactors identified by short run sequencing from the adapter end of the insert. The identity of potential interactors are ascertained by FASTA and BLAST searches against non-redundant and expressed sequence tag data bases at the national centre for biotechnology information ([www.ncbi.nlm.nih.gov/BLAST/](http://www.ncbi.nlm.nih.gov/BLAST/)) and European bioinformatics institute ([www.ebi.ac.uk/fasta33/](http://www.ebi.ac.uk/fasta33/)) interfaces, respectively, to identify characterized proteins cloned in frame with the GAL4 activation domain. Single pACT2 plasmids are then recovered by transformation of E. coli under ampicillin selection and positive interactions retested by cotransformation of AH109 with pGBKT7-SARG-1 and pACT2 containing the library insert selected by blue colony growth on -Ade, -His, -Leu, -Trp, X- $\alpha$ -gal plates. Bait and library genes are cloned into appropriate c-myc and HA epitope tagged eukaryotic expression vectors and interactions further confirmed by Western blotting of coimmunoprecipitated proteins either translated in vitro or from transiently cotransfected HEK 293 cells. The latter also allows colocalization experiments by confocal microscopical analysis following cloning and isolation of full length coding sequences. The cellular co-expression of interaction partners with SARG-1 is examined by either staining of sequential embryological slides generated with antibodies where available or by in situ hybridization of identified sequences. The identification of known binding partners enables the development of antisense or RNAi strategies to specifically reduce target expression or allows the use of specific functional inhibitors to further characterise the phenotypic changes seen in PC-12 apoptosis and differentiation. Binding partner identification also identifies the biochemical pathways which are influenced by SARG-1 expression which may also be specifically inhibited. Knockout models for identified binding partners may be crossed with the SARG-1 deficient mouse.

### Pitfall analysis

**[0056]** A relevant tissue is analysed where SARG-1 is highly expressed and plays a role in differentiation and apoptosis in a cell line model. Human gene banks are analysed to enable rapid identification of known RNA sequences. The SARG-1 sequence contains no cytoplasmic localization signals which could reduce transcriptional activation. Transfection of SARG-1 is not directly toxic to PC-12 or MeJuso cells and is therefore unlikely to be toxic in yeast. The matchmaker system uses multiple reporter genes with different promoter constructs to eliminate artefacts and has been used to isolate a number of binding partners (Corset et al, 2000; Galiegue et al, 1999; Ono et al, 2000; White et al, 2000). A eukaryotic cell line (HEK293) which allows efficient transient co-transfection of vector constructs is used to allow rapid screening of putative binding partners.

**[0057]** In a yeast two-hybrid analysis using the human SARG-1 protein as a bait to screen a human brain cDNA bank the following binding partners were isolated:

- 1: Homo sapiens protein-O-mannosyltransferase 1 (POMT1), (LC2)mRNA: (gi:12734916)
- 2: Homo sapiens microtubule-associated protein 1A (MAP1A), mRNA (XM\_012387)
- 3: Homo sapiens ATPase, Na<sup>+</sup>/K<sup>+</sup>-transporting, beta 1 polypeptide (ATP1B1, mRNA (gi:4502276)
- 4: Human SWI/SNF complex 60 KDa subunit (BAF60c) mRNA (gi: 1549246)

## EP 1 407 269 B1

5: Homo sapiens ACTN2 gene for alpha-Actinin 2, exon 16 (gi:6448557)

6: Homo sapiens rab GDP dissociation inhibitor 1 (GDI1), mRNA (gi:4503970)

7: Homo sapiens proteasome (prosome, macropain) 26S subunit, ATPase, 3(PSMC3), mRNA (gi: 4506210)

5 **[0058]** Of these binding proteins, especially the ATPase beta 1 polypeptide is of specific interest for use as a pharmaceutical target with respect to the binding to SARG-1.

### Generation of a conditional SARG-1 knockout mouse

10 **[0059]** Effective homologous recombination between vector construct and chromosomal target sequences is normally achieved by a species specific region of homology of 7kb with at least 2kb of homologous material adjacent to the drug resistance cassette (Johnson et al., 1995). The murine SARG-1 locus has been fully amplified by PCR (2420bp) and sequencing demonstrated the presence of 3 introns.

15 **[0060]** For construction of the replacement vector, approximately 2.5kb of additional non-coding chromosomal sequence information flanking the SARG-1 locus are obtained in the 129SvJ mouse. To this end, a radiolabelled SARG-1 cDNA sequence or a PCR product of the entire mSARG-1 locus is used to screen a 129SvJ mouse bacterial artificial chromosome (BAC) library (Incyte genomics) with an average insert size of 120kb or a 129SvJ mouse genomic library constructed in Lambda FIX<sup>®</sup> II phage (Stratagene) with insert sizes of 9 to 23kb, by standard methods. Following clone or phage isolation, genomic sequences flanking the coding region (approximately 2.5kb) is characterized by either direct sequencing of isolated clones with primers internal to the SARG-1 coding region, sequencing of cloned restriction fragments bearing SARG-1 sequences or by inverse PCR. The sequence information obtained is used to design PCR primers to insert 129SvJ mSARG-1 genomic sequences into the conditional/hypomorphic pDELBOY-3X targeting vector (Rossi et al, 2001). This vector incorporates features that overcomes problems potentially associated with gene deletion. Artificial phenotypes are generated in knockout mice due to the transcriptional activity of the neomycin cassette which can lead to disrupted regulation and splicing of the target locus and neighbouring genes (Pham et al, 1996; Olson et al, 1996). The neomycin cassette in the pDELBOY-3X vector is flanked by flip recombinase (frt) sites which permit efficient excision of the selection cassette in vitro and in vivo. Transient transfection of cells stably transfected with pDELBOY-3X with a vector expressing Flp recombinase leads to excision of the neomycin cassette.

25 **[0061]** Recently developed tools such as Flp recombinase-GFP fusion protein vectors, for example, allow enrichment of Flp-mediated recombination events in vitro by fluorescence activated cell sorting (Sabath et al., 2000). Conversely, crossing mice with the 129SvJ FLPer deleter mouse ubiquitously expressing enhanced FLP allows excision of the neomycin cassette in vivo. In addition, cloning of SARG-1 coding sequences between the loxP sites in the pDELBOY-3X vector permits generation of a null allele either in vitro by transfection with cre recombinase expressing plasmids or in vivo by crossing mice generated with animals expressing cre recombinase in a tissue specific manor. This strategy eliminates problems associated with heterozygote embryonic lethality and allows the precise tissue specific analysis of protein function. Knockout mice are generated by standard procedures (Papaioannou and Johnson, 2000; Gu et al, 1993). Briefly, embryonic stem cells (ES) are transfected by electroporation with linearized pDELBOY-3X-SARG-1 and homologous recombination events selected by neomycin/gancyclovir treatment and clones screened by PCR or southern blotting with a radiolabelled probe external to the targeting sequences. Blastocytes are isolated from 3.5 day pregnant mice, injected with ES clones and reimplanted in pseudopregnant mice. Following coat colour selection of chimeras, founder animals are mated with normal 129SvJ mice to produce a breeding line. Homozygotes are subsequently be obtained by inter-breeding. The phenotype of mice are screened by standard procedures. Analysis of histological sections prepared from embryonic and adult tissue, magnetic resonance imaging analysis combined with cell death assays such as TdT-mediated dUTP-X nick end labelling (TUNEL) provides direct evidence of the role of SARG-1 in differentiation and apoptosis, respectively, during development. Cellular analysis includes hematopoietic stem cell characterisation (colony forming assays, flow cytometrical analysis for cluster of differentiation antigens) and apoptotic response measurements in neural culture systems.

### Pitfall analysis

50 **[0062]** As described above, the pDELBOY-3X vector eliminates artefacts produced by transcription from the neomycin cassette and overcomes the problems of heterozygote embryonic lethality. Screening is also aided by the availability of animals which have a single mutation in the c-kit gene. Identification of SARG-1 binding partners for which knockout mice exist allows breeding with SARG-1 deficient mice to further clarify phenotype.

### Cellular localization

55 **[0063]** Balb/c mice are mated and embryos isolated at 7, 11 (Theiler's stages 10-19), 14 and 17 days and snap frozen

in liquid Nitrogen. 5µm transverse and sagittal consecutive sections are made on a cryostat and frozen until required. SARG-1 expression is analysed by standard immunohistochemical analysis on sections with anti-SARG-1 IgY which detects acetone-fixed mSARG-1. Expression patterns are identified by reference to standard embryological texts (Kaufman, 1992) and the mouse atlas and gene expression database project (<http://genex.hgu.mrc.ac.uk/>). Expression patterns in 17 days embryos are additionally correlated with those seen in adult murine tissue. Following identification of SARG-1 binding partners, co-expression studies are performed either by immunohisto-chemistry if antibodies are available or in situ hybridisation.

### Subcellular localization and biochemical characterization of epitope tagged SARG-1

**[0064]** The cytoplasmic, vesicular subcellular localization of SARG-1 is determined by double staining of HEK293, MelJuso or PC-12 cells stably transfected with epitope-tagged SARG-1. The HA tag is stained with rat monoclonal anti HA mAb and visualised with a biotinylated monoclonal anti-isotype mAb followed by fluorochrome conjugated streptavidin (FITC, S, phycoerythrin or cy5). Organelle localized antigens are detected with antibodies to Bip/GRP78 (endoplasmic reticulum), β-cop (Golgi complex), Lamp-1 (lysosomes) and Ab-2 (mitochondria) either conjugated directly or by the use of second step antibodies and analysed on a Zeiss laser scan microscope. Cloned and native SARG-1 (predicted mass 17Kd) migrates at 28Kd in SDS-PAGE. Glycosylation of HA-tagged SARG-1 is initially investigated by immunoprecipitation on an anti-HA matrix and detection of glycosylated residues by periodate oxidation, incorporation of biotin hydrazide and detection with strep-tavidin conjugated alkaline phosphatase on western blots. N- and O-specific enzymatic deglycosylation reactions are performed with PNGase F and O-Glycosidase (Bio-Rad), respectively, and the molecular weight of SARG-1 monitored by western blotting. The SARG-1 sequence contains consensus protein kinase C and casein kinase II sites which are known to phosphorylate apoptotic regulators (Verma et al, 2001). The phenotypical differences seen between Trk activation by NGF which leads to PKC activation (Patapoutian et al., 2001) and treatment with the protein kinase inhibitor staurosporine in PC-12 possibly suggesting regulation of SARG-1 function by phosphorylation. To examine possible SARG-1 phosphorylation, immunoprecipitated SARG-1 is probed with polyclonal antibodies against phosphothreonine and phosphoserine in Western blotting analysis and compared to phosphatase-treated protein. Mutant SARG-1 eukaryotic expression plasmids are then generated by site directed mutagenesis to delete potential casein kinase II phosphorylation sites and used to transfect PC-12 cells to monitor the effects of the protein kinase inhibitor staurosporine.

### Analysis of Mutation in MS Samples

**[0065]** The immunohistochemical localisation of SARG-1 protein to the grey and white matter of the CNS and the role of SARG-1 in apoptotic induction prompted a candidate gene approach to analyse the mutational status of SARG-1 in cases of familial MS. The DNA from twenty unrelated familial multiple sclerosis patients was examined by PCR amplification of the SARG-1 locus and DNA sequencing and compared to SARG-1 sequences from healthy controls. All control samples demonstrated wild type SARG-1 genomic sequences. From MS patients, only 6 from 20 DNA samples were able to be amplified by PCR. Primer sets used spanned the whole coding region, intron 2/exon 3, and primer pairs specific for exons 1, 2 and 3. Control GAPDH primers were positive for all samples. In 6/20 samples that produced a PCR product, amplicants were TA cloned into the pCR<sup>®</sup>II vector (Invitrogen) and sequenced. In 4/6 patients, genetic alterations were seen. A T → C point mutation at nucleotide 67 resulting in the substitution of phenylalanine for leucine amino acid 23 (Fig 16). A C → T point mutation at nucleotide 359 resulting in the substitution of phenylalanine for serine at amino acid 120 (Fig 17). An A → G point mutation at nucleotide 89 resulting in the substitution of glycine for glutamic acid at amino acid 30 (Fig 18). Deletion of a codon between amino acids 116 and 121 resulting in the loss of a serine residue (Fig 19). Sequencing of over 20 control DNA samples revealed only wild type sequence.

### Polymorphisms and Other Mutations

**[0066]** In sequence analysis of over 30 cancer cell lines, a polymorphism in the human sequence at nucleotide 280 (coding sequence) results in either valine (g residue; shown), methionine (a) or leucine (t) residues at position 94 of the amino acid sequence. In a human melanoma cell line, two mutations in SARG-1 are found: an A → G point mutation at nucleotide 74 resulting in the substitution of aspartic acid for glycine and a C → T point mutation at nucleotide 289 resulting in the substitution of histidine for tyrosine at amino acid 97. Such SARG-1 mutations therefore are suitable markers for human melanomas.

TABLE

67 T → C = F → L 23

## EP 1 407 269 B1

(continued)

5	74	A → G	=	E → G	25
	89	A → G	=	E → G	30
	289	C → T	=	H → Y	97
	359	C → T	=	S → F	120
	Δ			S	116-121

### References

- 10 **[0067]**
- Bauer et al. (1993), NAR: 21: 4272-4280
- 15 Bench et al. (2000), Oncogene 19, 3902-3913
- Chataway et al. (1998), Brain 121, 1869-1887
- Corset et al. (2000), Nature 407: 747-750
- 20 Deloukas et al. (2001), Nature 414: 865-871
- Ebers et al. (1995), Nature 377, 150-151
- 25 Fraker, in "Cell death", edited by Schwartz et al., Methods in Cell Biology, Vol 46, Academic press, San Diego, CA pp57-76
- Fu et al. (1999), J. Biol.Chem. 274, 7264-7271
- 30 Galiegue et al. (1999), J.Biol.Chem. 274: 2938-2952
- Gu et al. (1993), Cell 73: 1155-1164
- Haines et al. (1998) Hum.Mol.Genet. 7, 1229-1234
- 35 Hashimoto et al. (1989), Exp. Cell Res., 184, 351-359
- Jacobson et al. (2000) Nature Genetics, 26, 495-499
- 40 Johnson et al. (1995), Gene Probes 2, A Practical Approach, Oxford University Press, chapter 12, 313-327
- Kaufman (1992), "The Atlas of Mouse Development" Academic Press, London
- Liang et al. (1992), Science: 257: 967-971
- 45 Liang et al. (1993), NAR: 21: 3269-3275
- Liang et al. (1995), Current opinions in Immunology: 7: 274-280
- 50 Lucas et al. (1999), FASEB J. 13, 263-272
- Olson et al. (1996), Cell 5: 1-4
- Ono et al. (2000), J. Biol.Chem. 275: 31145-31154
- 55 Papaioannou et al. (2000) in "Gene Targeting - A Practical Approach" ed. by Joyner
- Patapoutian et al. (2001), Curr. Opin. Neurobiol.11: 272-280

**EP 1 407 269 B1**

Pham et al. (1996), PNAS 93: 13090-13095

Rechsteiner et al. (1996), TIBS 21: 267-271

5 Rossi et al. (2001), EMBO j. 20: 2844-2856

Sabath et al. (2000), Biotechniques 5: 966-972

10 Sadovnick et al. (2000), Clin. Genet. 58, 431-435

Sambrock et al. (1989), Molecular cloning a laboratory manual (second edition).

Sawcer et al. (1998), Curr. Opin. Immunol. 10, 697-703

15 Verma et al. (2001), J. Biol.Chem. 276: 4671-4676

Wattel et al. (1993), Leuk. Res. 17: 921-926

20 Weinshenker et al. (2000), Neurology, 54, 542-544

White et al. (2000), PNAS 97: 13967-13972

Zipp (2000), Cell Tissue Res. 301, 163-171

25 SEQUENCE LISTING

**[0068]**

30 <110> Burkhard Dr., Jansen  
Lucas Dr., Trevor

<120> Method for diagnosing a person having MS or being at risk of developing MS

35 <130> method for diagnosing MS

<140>

<141>

40 <160> 13

<170> PatentIn Ver. 2.1

<210> 1

<211> 486

45 <212> DNA

<213> human

<400> 1

50

55

EP 1 407 269 B1

atggacccaa atcctcgggc cgccctggag cgccagcagc tccgccttcg ggagcggcaa 60  
 aaattcttcg aggacathtt acagccagag acagagtttg tctttcctct gtcccatctg 120  
 5 catctcgagt cgcagagacc ccccataggt agtatctcat ccatggaagt gaatgtggac 180  
 aactgggagc aagtagaact tattgacctt ggggaccgg atgcagcaga tgtgttcttg 240  
 ccttgcaag atcctccacc aacccccag tcgtctgggg tggacaacca tttggaggag 300  
 ctgagcctgc cgggtgcctac atcagacagg accacatcta ggacctctc ctcctcctc 360  
 10 tccgactcct ccaccaacct gcatagccca aatccaagt atgatggagc agatagccc 420  
 ttggcacagt cggatgaaga ggaggaaagg ggtgatggag gggcagagcc tggagcctgc 480  
 agctag 486

15 <210> 2  
 <211> 161  
 <212> PRT  
 <213> human

20 <400> 2

Met Asp Pro Asn Pro Arg Ala Ala Leu Glu Arg Gln Gln Leu Arg Leu  
 1 5 10 15  
 25 Arg Glu Arg Gln Lys Phe Phe Glu Asp Ile Leu Gln Pro Glu Thr Glu  
 20 25 30  
 30 Phe Val Phe Pro Leu Ser His Leu His Leu Glu Ser Gln Arg Pro Pro  
 35 40 45

35

40

45

50

55

EP 1 407 269 B1

Ile Gly Ser Ile Ser Ser Met Glu Val Asn Val Asp Thr Leu Glu Gln  
50 55 60

5

Val Glu Leu Ile Asp Leu Gly Asp Pro Asp Ala Ala Asp Val Phe Leu  
65 70 75 80

10

Pro Cys Glu Asp Pro Pro Pro Thr Pro Gln Ser Ser Gly Val Asp Asn  
85 90 95

15

His Leu Glu Glu Leu Ser Leu Pro Val Pro Thr Ser Asp Arg Thr Thr  
100 105 110

Ser Arg Thr Ser Ser Ser Ser Ser Ser Asp Ser Ser Thr Asn Leu His  
115 120 125

20

Ser Pro Asn Pro Ser Asp Asp Gly Ala Asp Thr Pro Leu Ala Gln Ser  
130 135 140

25

Asp Glu Glu Glu Glu Arg Gly Asp Gly Gly Ala Glu Pro Gly Ala Cys  
145 150 155 160

Ser

30

<210> 3  
<211> 1083

35

<212> DNA  
<213> human

<400> 3

40

45

50

55

EP 1 407 269 B1

ccaggccgga gccaggggcc ccaactgttg gatgctggct gcagtggggc gcccgaagcc 60  
 caggtcccct ctgtcttctc ttctgacttt gcagctgtac ttgttttgct cctctacccg 120  
 caggagctga catggaccca aatcctcggg ccgcccctgga gcgccagcag ctccgccttc 180  
 5 gggagcggca aaaattcttc gaggacattt tacagccaga gacagagttt gtctttctc 240  
 tgtcccatct gcatctcgag tcgcagagac ccccatagg tagtatctca tccatggaag 300  
 tgaatgtgga cacactggag caagtagaac ttattgacct tggggacccg gatgcagcag 360  
 atgtgttctt gecttgcgaa gatectccac caacccccca gtcgtctggg gtggacaacc 420  
 10 atttggagga gctgagcctg ccggtgccta catcagacag gaccacatct aggacctcct 480  
 cctcctctc ctccgactcc tccaccaacc tgcatagcc aaatccaagt gatgatggag 540  
 cagatacgcc cttggcacag tcggatgaag aggaggaaag gggatgatgga ggggcagagc 600  
 ctggagcctg cagctagcag tgggcccctg cctacagact gaccacgctg gctattctcc 660  
 15 acatgagacc acaggccag ccagagcctg tcgggagaag accagactct ttacttgag 720  
 taggcaccag aggtgggaag gatggtggga ttgtgtacct ttctaagaat taaccctctc 780  
 ctgctttact gctaattttt tctgtgtgca accctcccac cagtttttg cttactctg 840  
 agatatgatt tgcaaatgag gagagagaag atgaggttg acaagatgcc actgcttttc 900  
 20 ttagcactct tccctcccct aaaccatccc gtagtcttct aatacagtct ctcagacaag 960  
 tgtctctaga tggatgtgaa ctcttaact catcaagtaa ggtggtactc aagccatgct 1020  
  
 25 gctccttac atcctttttg gaacagagca cggataaat aataaactaa taataatg 1080  
 cca 1083

30 <210> 4  
 <211> 1038  
 <212> DNA  
 <213> rat

35 <400> 4

40

45

50

55

EP 1 407 269 B1

ccagactgga agcgaaggct gtgttgctog gatgccagct gccgaggggc tgcttaagcc 60  
 ttggceccca ctactttctg tttcagcccc acttctgtgc gtgttact ccattacccc 120  
 caggggctga catggaccca aatccacgag cagccctgga gggcagcag ctgcgtctca 180  
 5 gggagcggca gaagttcttc gaggacattt tacagccaga gacagagttt gttttcccc 240  
 tatcccatct gcatctcgag tcacaaagac ccccatagg tagcatctcc tcgatggaag 300  
 tgaatgtgga cacactggag caggtggaat ttattgacct tgcggatcag gatggagcag 360  
 atgtgttctt accttgtgag gattctcttc caactcccca gaggtctgga gtggatgacc 420  
 10 accagagga gctgagcctg ctggtacca cgtcagacag gaccacatcc cggacctcct 480  
 ccttgtcctc tgactcctcc aacctgcgca gtccaaatcc aagtgatggg ggaggagaca 540  
 ctccctggc acagtctgac gaggaggatg gggacggtgg aggggcagaa cctggacctt 600  
 gcagctagca gaggcccctt acaaactgag cgatctggct gttctccatg gagaggagac 660  
 15 cttaggtcca ccagagcact ctggagaaga cctgacactt tacttacatc agcaccaaag 720  
 ggaggggaagg atggtggatg gtgtgcctga gagttagcct ccccgttta ctgataacgc 780  
 tgtcctgctg ccacgcccc acagtgcctt cttctgaggt aggacttcca agtgagactc 840  
 tcgaaggtga ggtgggacaa gatgccactg tttcttact cccctcctgc ccccaaatga 900  
 20 tcctgtagtc tccactagt ctctaaagc agtgtctctg agggaaagt ctgaggagtt 960  
 ccactttgca gttatctgc ctctataagt ctttctggg aacaggatat ggtataaata 1020  
 ataaataata ctgtacca 1038

25 <210> 5  
 <211> 486  
 <212> DNA  
 <213> rat

30 <400> 5

atggacccaa atcctcgggc egccctggag cgccagcagc tccgccttcg ggagcggcaa 60  
 aaattcttcg aggacatttt acagccagag acagagtttg tcttctctct gtcccatctg 120  
 35 catctcgagt cgcagagacc ccccatagggt agtatctcat ccatggaagt gaatgtggac 180  
 acactggagc aagtagaact tattgacctt ggggaccggt atgcagcaga tgtgttcttg 240  
 ccttgcaag atcctccacc aacccccag tcgtctggga tggacaacca tttggaggag 300  
 ctgagcctgc cgggtgcctac atcagacagg accacatcta ggacctctc ctctccttc 360  
 40 tccgactcct ccaccaacct gcatagccca aatccaagt atgatggagc agatacgccc 420  
 ttggcacagt cggatgaaga ggaggaaagg ggtgatggag gggcagagcc tggagcctgc 480  
 agctag 486

45 <210> 6  
 <211> 158  
 <212> PRT  
 <213> rat

50 <400> 6

55



EP 1 407 269 B1

5  
 10  
 15  
 20  
 25

```

ggatccaacg cgggcgctgc tcgctccac gccccgccc ccgcttgctg ggagcgcacc 60
cagggagcca gcggggcgcg ggcgctgcag gggctgacat ggacccaaat ccgagagcag 120
ccctggagcg ccaacagctg cggctccggg agaggcagaa gttctttgag gacattttac 180
agccagagac agagtttgtc tccccctgt cccatctgca cctggagtca caaagacccc 240
ccataggtag catctcgtct atggaagtga atgtggacac actggagcaa gtggagttta 300
ttgatcttgc ggatcaggat ggagcagatg tgttcttgcc ttgtgaggag tcctcgccag 360
ctccccagat gtctggagtg gatgaccatc cagaggagct gagcctgctg gtaccacagt 420
ctgacaggac cacatccccg acctcctcct tgtcctctga ctctccaac ctgcgcagtc 480
caaatccaag tgatggggga ggagacactc cettggcaca gtctgatgag gaggacgggg 540
  
```

30  
 35  
 40  
 45  
 50

```

atgacggagg ggcagagcct ggaccctgca gctagcagtg ggcctcgtac agactgacca 600
gccccgctgt tctccatgga aaggagacct aggccagca gagcctggag aagacctgac 660
actttcctta cttcagcacc aaagggaggg aaggatgggt gatggtgtgc ctgagagtta 720
gcctcccctg ctttaccgta acgctatcct gctgccacgc cccacagtg cttttcttct 780
gaggtaggac ttccaagtga gacttgagag gtgaggtggg acaagacgca gctgctttct 840
tagtcccctc ctgccccag atgatcctgt tgtcttcac agagtctcct aagccagtgt 900
ctctgagggg atgttctgag gagttccact ttccagttat cctgcctcta taagttcttt 960
tgggaacagg atatggtata aataataaat aataatatac ca 1002
  
```

30  
 35

```

<210> 8
<211> 477
<212> DNA
<213> mouse
  
```

35

```

<400> 8
  
```

40  
 45  
 50

```

atggacccaa atccgagagc agccctggag cgccaacagc tgcggctccg ggagagggcag 60
aagttctttg aggacatttt acagccagag acagagtttg tcttcccct gtcccatctg 120
cacctggagt cacaagacc ccccataggt agcatctcgt ctatggaagt gaatgtggac 180
aactggagc aagtggagtt tattgatctt gcggatcagg atggagcaga tgtgttcttg 240
cctgtgagg agtcctgcc agctccccag atgtctggag tggatgacca tccagaggag 300
ctgagcctgc tggtagccac gtctgacagg accacatccc ggacctctc cttgtcctct 360
gactcctcca acctgcgag tccaaatcca agtgatgggg gaggagacac tcccttgga 420
cagtctgatg aggaggacgg ggatgacgga ggggcagagc ctggaccctg cagctag 477
  
```

50  
 55

```

<210> 9
<211> 158
<212> PRT
<213> mouse
  
```

55

```

<400> 9
  
```



EP 1 407 269 B1

Met Asp Pro Asn Pro Arg Ala Ala Leu Glu Arg Gln Gln Leu Arg Leu  
 1 5 10 15  
 5 Arg Glu Arg Gln Lys Phe Leu Glu Asp Ile Leu Gln Pro Glu Thr Glu  
 20 25 30  
 10 Phe Val Phe Pro Leu Ser His Leu His Leu Glu Ser Gln Arg Pro Pro  
 35 40 45  
 15 Ile Gly Ser Ile Ser Ser Met Glu Val Asn Val Asp Thr Leu Glu Gln  
 50 55 60  
 Val Glu Leu Ile Asp Leu Gly Asp Pro Asp Ala Ala Asp Val Phe Leu  
 65 70 75 80  
 20 Pro Cys Glu Asp Pro Pro Pro Thr Pro Gln Ser Ser Gly Val Asp Asn  
 85 90 95  
 25 His Leu Glu Glu Leu Ser Leu Pro Val Pro Thr Ser Asp Arg Thr Thr  
 100 105 110  
 Ser Arg Thr Ser Ser Ser Ser Ser Ser Asp Ser Ser Thr Asn Leu His  
 115 120 125  
 30 Ser Pro Asn Pro Ser Asp Asp Gly Ala Asp Thr Pro Leu Ala Gln Ser  
 130 135 140  
 35 Asp Glu Glu Glu Glu Arg Gly Asp Gly Gly Ala Glu Pro Gly Ala Cys  
 145 150 155 160

40

Ser

45 <210> 11  
 <211> 161  
 <212> PRT  
 <213> human

50 <400> 11

55

EP 1 407 269 B1

Met Asp Pro Asn Pro Arg Ala Ala Leu Glu Arg Gln Gln Leu Arg Leu  
 1 5 10 15  
 5 Arg Glu Arg Gln Lys Phe Phe Glu Asp Ile Leu Gln Pro Glu Thr Glu  
 20 25 30  
 10 Phe Val Phe Pro Leu Ser His Leu His Leu Glu Ser Gln Arg Pro Pro  
 35 40 45  
 15 Ile Gly Ser Ile Ser Ser Met Glu Val Asn Val Asp Thr Leu Glu Gln  
 50 55 60  
 Val Glu Leu Ile Asp Leu Gly Asp Pro Asp Ala Ala Asp Val Phe Leu  
 65 70 75 80  
 20 Pro Cys Glu Asp Pro Pro Pro Thr Pro Gln Ser Ser Gly Val Asp Asn  
 85 90 95  
 25 His Leu Glu Glu Leu Ser Leu Pro Val Pro Thr Ser Asp Arg Thr Thr  
 100 105 110  
 Ser Arg Thr Ser Ser Ser Ser Phe Ser Asp Ser Ser Thr Asn Leu His  
 115 120 125  
 30 Ser Pro Asn Pro Ser Asp Asp Gly Ala Asp Thr Pro Leu Ala Gln Ser  
 130 135 140  
 35 Asp Glu Glu Glu Glu Arg Gly Asp Gly Gly Ala Glu Pro Gly Ala Cys  
 145 150 155 160  
 40 Ser

<210> 12  
 <211> 161  
 45 <212> PRT  
 <213> human

<400> 12

50

55



Phe Val Phe Pro Leu Ser His Leu His Leu Glu Ser Gln Arg Pro Pro  
 35 40 45  
 5  
 Ile Gly Ser Ile Ser Ser Met Glu Val Asn Val Asp Thr Leu Glu Gln  
 50 55 60  
 10  
 Val Glu Leu Ile Asp Leu Gly Asp Pro Asp Ala Ala Asp Val Phe Leu  
 65 70 75 80  
 15  
 Pro Cys Glu Asp Pro Pro Pro Thr Pro Gln Ser Ser Gly Val Asp Asn  
 85 90 95  
 20  
 His Leu Glu Glu Leu Ser Leu Pro Val Pro Thr Ser Asp Arg Thr Thr  
 100 105 110  
 25  
 Ser Arg Thr Ser Ser Ser Ser Ser Asp Ser Ser Thr Asn Leu His Ser  
 115 120 125  
 30  
 Pro Asn Pro Ser Asp Asp Gly Ala Asp Thr Pro Leu Ala Gln Ser Asp  
 130 135 140  
 35  
 Glu Glu Glu Glu Arg Gly Asp Gly Gly Ala Glu Pro Gly Ala Cys Ser  
 145 150 155 160

**Claims**

1. Method for diagnosing a person having multiple sclerosis (MS) or being at risk of developing MS, comprising the following steps:
  - detecting the presence or absence of wild type SCF-Apoptosis-Response Gene- (wt-SARG-1-) protein and/or nucleic acids encoding wt-SARG-1 in a sample of a body fluid or tissue from said person, and
  - diagnosing MS or a risk of acquiring MS, if wt-SARG-1-protein or nucleic acids encoding wt-SARG-1 are not present in said sample or not diagnosing MS, or a risk of acquiring MS, if wt-SARG-1-protein or nucleic acids encoding wt-SARG-1 are present in said sample.
2. Method according to claim 1, wherein said sample is derived from human blood, plasma, serum, lymph, nerve-cell containing tissue, cerebrospinal fluid, all biopsy-material, including tumor tissue, bone marrow, nervous tissue, skin, hair, tears, fetal material including amniocentesis material, uterine tissue, saliva, faeces or sperm.
3. Method according to claims 1 or 2, wherein nucleic acids encoding wt-SARG-1 are detected by a method selected from the group consisting of a nucleic acid amplification method, single-strand conformation polymorphism (SSCP) analysis, restriction analysis, microarray technology and proteomics.
4. Method according to claim 3, wherein said nucleic acid amplification method is a polymerase chain reaction method.
5. Method according to any one of claims 1 to 4, wherein said wt-SARG-1-protein is detected using a wt-SARG-1-protein antibody, especially a monoclonal antibody.

## EP 1 407 269 B1

6. Method according to any one of claims 1 to 5, wherein said detecting the presence of wt-SARG-1-protein or nucleic acids encoding wt-SARG-1 is performed within a screening test.
- 5 7. Nucleic acid molecule comprising a sequence according to Seq.ID.No.1, wherein one nucleic acid residue is exchanged by a different nucleic acid residue, wherein the exchange is selected from a T to C exchange at position 67 of Seq.ID.No.1, a A to G exchange at position 89 of Seq.ID.No.1 and a C to T exchange at position 359 of Seq.ID.No.1.
- 10 8. Polypeptide according to Seq.ID.No. 2, wherein one amino acid is exchanged and said exchange is selected from Phe23 to Leu23, Glu30 to Gly30 and Ser120 to Phe120.
- 15 9. Use of a kit comprising means for detecting the presence of wt-SARG-1-protein or nucleic acids encoding wt-SARG-1 for diagnosing MS in a sample of a body fluid or tissue, wherein said means are selected from anti wt-SARG-1 protein antibodies, nucleic acid probes selectively binding to wt-SARG-1, nucleic acid primers defining a region being selective for wt-SARG-1; or a chip comprising said nucleic acid probes or said nucleic acid primers.

### Patentansprüche

- 20 1. Verfahren zum Diagnostizieren einer Person mit Multipler Sklerose (MS) oder bei der ein Risiko zur Entwicklung von MS besteht, das die folgenden Schritte umfasst:
- 25 - Nachweisen des Vorhandenseins oder der Abwesenheit des Wildtyp SCF-Apoptosis-Response-Gen (wt-SARG-1)-Proteins und/oder von Nucleinsäuren, die wt-SARG-1 kodieren, in einer Probe von einer Körperflüssigkeit oder von einem Körpergewebe der Person, und
- 30 - Diagnostizieren von MS oder eines Risikos der Entwicklung von MS, wenn das wt-SARG-1-Protein oder die Nucleinsäuren, die wt-SARG-1 kodieren, nicht in der Probe vorhanden sind oder kein Diagnostizieren von MS oder eines Risikos der Entwicklung von MS, wenn das wt-SARG-1-Protein oder die Nucleinsäuren, die wt-SARG-1 kodieren, in der Probe vorhanden sind.
- 35 2. Verfahren nach Anspruch 1, wobei die Probe aus menschlichem Blut, Plasma, Serum, Lympheflüssigkeit, Nervenzellen-enthaltendem Gewebe, Cerebrospinalflüssigkeit, aus jeglichem Biopsiematerial einschließlich Tumorgewebe, Knochenmark, Nervengewebe, Haut, Haare, Tränenflüssigkeit, aus fötalem Material einschließlich Amnionzentese material, Gebärmuttergewebe, Speichel, Stuhl oder Sperma erhalten ist.
- 40 3. Verfahren nach Anspruch 1 oder 2, wobei die Nucleinsäuren, die wt-SARG-1 kodieren, durch ein Verfahren nachgewiesen werden, das ausgewählt ist aus der Gruppe, bestehend aus einem Nucleinsäure-Amplifikationsverfahren, Einzelstrang-Konformationspolymorphismus-(SSCP)Analyse, Restriktionsanalyse, Mikroarray-Technologie und Proteomik.
- 45 4. Verfahren nach Anspruch 3, wobei das Nucleinsäure-Amplifikationsverfahren ein Polymerasekettenreaktions-Verfahren ist.
- 50 5. Verfahren nach einem der Ansprüche 1 bis 4, wobei das wt-SARG-1-Protein unter Verwendung von einem Antikörper, insbesondere von einem monoklonalen Antikörper, gegen das wt-SAR-G-1-Protein nachgewiesen wird.
- 55 6. Verfahren nach einem der Ansprüche 1 bis 5, wobei der Nachweis für das Vorhandensein von dem wt-SARG-1-Protein oder von den Nucleinsäuren, die wt-SARC-1 kodieren, innerhalb eines Screening-Tests durchgeführt wird.
7. Nucleinsäuremolekül, das eine Sequenz nach Seq.-ID Nr. 1 umfasst, wobei ein Nucleinsäurerest durch einen unterschiedlichen Nucleinsäurerest ausgetauscht ist, wobei der Austausch aus einem T gegen C-Austausch an Position 67 von Seq.-ID Nr. 1, einem A gegen G-Austausch an Position 89 von Seq.-ID Nr. 1 und einem C gegen T-Austausch an Position 359 von Seq.-ID Nr. 1 ausgewählt ist.
8. Polypeptid nach Seq.-ID Nr. 2, wobei eine Aminosäure ausgetauscht ist und der Austausch ausgewählt ist aus einem Austausch von Phe23 gegen Leu23, Glu30 gegen Gly30 und Ser120 gegen Phe120.
9. Verwendung von einem Kit, das Mittel zum Nachweisen des Vorhandenseins von dem wt-SARG-1-Protein oder

## EP 1 407 269 B1

von Nukleinsäuren umfasst, die wt-SARG-1 kodieren, für die Diagnose von MS in einer Probe von einer Körperflüssigkeit oder einem Körpergewebe, wobei die Mittel ausgewählt sind aus Antikörpern gegen das wt-SARG-1-Protein, aus Nukleinsäuresonden, die selektiv an wt-SARG-1 binden, aus Nukleinsäureprimern, die einen Bereich festlegen, der für wt-SARG-1 selektiv ist; oder einen Chip, der die Nukleinsäuresonden oder die Nukleinsäureprimer umfasst.

### Revendications

1. Procédé pour diagnostiquer une personne ayant la sclérose en plaques (MS) ou risquant de développer une MS, comprenant les étapes suivantes :
  - détection de la présence ou de l'absence de la protéine (wt-SARG-1) du gène de la réaction d'apoptose à SCF de type sauvage et/ou d'acides nucléiques codant wt-SARG-1 dans un échantillon d'un liquide ou tissu corporel provenant de ladite personne, et
  - diagnostic de MS ou du risque de contracter une MS si la protéine wt-SARG-1 ou les acides nucléiques codant wt-SARG-1 ne sont pas présents dans ledit échantillon ou non-diagnostic de MS ou du risque de contracter une MS si la protéine wt-SARG-1 ou les acides nucléiques codant wt-SARG-1 sont présents dans ledit échantillon.
2. Procédé selon la revendication 1, où ledit échantillon provient de sang humain, de plasma, de sérum, de lymphe, de tissu contenant des neurones, de liquide céphalorachidien, de tous les matériels de biopsie, y compris le tissu tumoral, de moelle osseuse, de tissu nerveux, de peau, de cheveux et poils, de larmes, de matériel foetal y compris le matériel d'amniocentèse, de tissu utérin, de salive, de fèces ou de sperme.
3. Procédé selon la revendication 1 ou 2, où les acides nucléiques codant wt-SARG-1 sont détectés par un procédé sélectionné dans le groupe constitué d'un procédé d'amplification d'acide nucléique, d'une analyse de polymorphisme conformationnel monobrin (SSCP), d'une analyse de restriction, de la technologie des puces et de la protéomique.
4. Procédé selon la revendication 3, où ledit procédé d'amplification d'acide nucléique est un procédé de réaction de polymérisation en chaîne.
5. Procédé selon l'une quelconque des revendications 1 à 4, où ladite protéine wt-SARG-1 est détectée au moyen d'un anticorps anti-protéine wt-SARG-1, notamment un anticorps monoclonal.
6. Procédé selon l'une quelconque des revendications 1 à 5, où ladite détection de la présence de la protéine wt-SARG-1 ou d'acides nucléiques codant wt-SARG-1 est réalisée dans le cadre d'un test de dépistage.
7. Molécule d'acide nucléique comprenant une séquence selon SEQ ID No. 1, où un résidu acide nucléique est remplacé par un résidu acide nucléique différent, où le remplacement est sélectionné parmi un remplacement de T par C à la position 67 de SEQ ID No. 1, un remplacement de A par G à la position 89 de SEQ ID No. 1 et un remplacement de C par T à la position 359 de SEQ ID No. 1.
8. Polypeptide selon SEQ ID No. 2, où un acide aminé est remplacé et ledit remplacement est sélectionné parmi Phe23 à Leu23, Glu30 à Gly30 et Ser120 à Phe120.
9. Utilisation d'un kit comprenant un moyen de détection de la présence de la protéine wt-SARG-1 ou d'acides nucléiques codant wt-SARG-1 pour diagnostiquer une MS dans un échantillon d'un liquide ou tissu corporel, où ledit moyen est sélectionné parmi des anticorps anti-protéine wt-SARG-1, des sondes d'acides nucléiques se liant sélectivement à wt-SARG-1, des amorces d'acides nucléiques définissant une région sélective pour wt-SARG-1 ; ou une puce comprenant lesdites sondes d'acides nucléiques ou lesdites amorces d'acides nucléiques.




FIG.1




FIG. 2




FIG. 3

```

>rSARG, 1037 bases
CCAGACTGGAAGCGAAGGCTGTGTTGCTGGGATGCCAGCTGCCGAGGGGG
TGCTTAAGCCTTGGCCCCACTACTTTCTGTTTCAGCCCCACTTCTGTGC
GTGTCTTACTCCATTACCCCCAGGGGCTGACATGGACCCAAATCCACGAG
CAGCCCTGGAGCGGCAGCAGCTGCGTCTCAGGGAGCGGCAGAAGTTCTTC
GAGGACATTTTACAGCCAGAGACAGAGTTTGTTTTCCCCCTATCCCATCT
GCATCTCGAGTCACAAAGACCCCCATAGGTAGCATCTCCTCGATGGAAG
TGAATGTGGACACACTGGAGCAGGTGGAATTTATTGACCTTGGGATCAG
GATGGAGCAGATGTGTTCTTACCTTGTGAGGATTTCTCCTCCAACCTCCCA
GAGGTCTGGAGTGGATGACCACCCAGAGGAGCTGAGCCTGCTGGTACCCA
CGTCAGACAGGACCACATCCCGGACCTCCTCCTTGTCTCTGACTCCTCC
AACCTGCGCAGTCCAAATCCAAGTGATGGGGGAGGAGACTCCCTTGGC
ACAGTCTGACGAGGAGGATGGGGACGGTGGAGGGGCAGAACCTGGACCTT
GCAGCTAGCAGAGGCCCTTACAACTGAGCGATCTGGCTGTTCTCCATG
GAGAGGAGACCTTAGGTCCACCAGAGCACTCTGGAGAAGACCTGACACTT
TACTTACATCAGCACCAAAGGGAGGGAAGGATGGTGGATGGTGTGCCTGA
GAGTTAGCCTCCCGCTTACTGATAACGCTGTCTCTGCCACGCCCC
ACAGTGTCTTCTTCTGAGGTAGGACTTCCAAGTGAGACTCTCGAAGGTGA
GGTGGGACAAGATGCCACTGTTTTCTTACTCCCCTCTGCCCCAAATGA
TCCTGTAGTCTCCACTAGTCTCCTAAGCCAGTGTCTCTGAGGGAAAGTT
CTGAGGAGTTCCACTTTGCAGTTATCCTGCCTCTATAAGTCTTTCTGGG
AACAGGATATGGTATAAATAATAAATAATACTGTACC

>mSARG, 1029 bases
CCAGACCGGAAGCGAGGCTGTGTTGCTGGGATCCAACGCCGGCGCTGCTC
GCTCCCACGCCCCCGCCGCTTGTGCGGAGCGCACCCAGGGAGCCAGC
GGGGCGGGGCGCTGCAGGGGCTGACATGGACCCAAATCCGAGAGCAGCC
CTGGAGCGCCAACAGCTGCGGCTCCGGGAGAGGCAGAAGTTCTTTGAGGA
CATTTTACAGCCAGAGACAGAGTTTGTCTTCCCCCTGTCCCATCTGCACC
TGGAGTCACAAAGACCCCCCATAGGTAGCATCTCGTCTATGGAAGTGAAT
GTGGACACACTGGAGCAAGTGGAGTTTATTGATCTTGGGATCAGGATGG
AGCAGATGTGTTCTTGCCTTGTGAGGAGTCTCGCCAGCTCCCCAGATGT
CTGGAGTGGATGACCATCCAGAGGAGCTGAGCCTGCTGGTACCCACGCTT
GACAGGACCACATCCCGGACCTCCTCCTTGTCTCTGACTCCTCCAACCT
GCGCAGTCCAAATCCAAGTGATGGGGGAGGAGACTCCCTTGGCACAGT
CTGATGAGGAGGACGGGGATGACGGAGGGGCAGAGCCTGGACCCCTGCAGC
TAGCAGTGGGCTCGTACAGACTGACCAGCCCGGCTGTTCTCCATGGAAA
GGAGACCTAGGCCCAGCAGAGCCTGGAGAAGACCTGACACTTTCCTTACT
TCAGCACCAAAGGGAGGGAAGGATGGTGGATGGTGTGCCTGAGAGTTAGC
CTCCCCTGCTTTACCGTAACGCTATCCTGCTGCCACGCCCCACAGTGCT
TTCTTCTGAGGTAGGACTTCCAAGTGAGACTTGAGAGGTGAGGTGGGAC
AAGACGCAGCTGCTTTCTTAGTCCCTCCTGCCCCAGATGATCCTGTTG
TCTTCCACAGAGTCTCCTAAGCCAGTGTCTCTGAGGGGATGTTCTGAGGA
GTTCCACTTTCAGTTATCCTGCCTCTATAAGTTCTTTTGGGAACAGGAT
ATGGTATAAATAATAAATAATAATATACC

>hSARG, 1082 bases
CCAGGCCGGAGCCAGGGGCCCTACTGTGGGATGCTGGCTGCAGTGGGGC
GCCCAAGCCAGGTCCCCTCTGTCTTCTCTTTGACTTTGCAGCTGTAC
TTGTTTGTCTCCTCTACCCGCAGGAGCTGACATGGACCCAAATCCTCGGG
CCGCCCTGGAGCGCCAGCAGCTCCGCCCTTCGGGAGCGGCAAAAATTTCTTC
GAGGACATTTTACAGCCAGAGACAGAGTTTGTCTTTCCCTGTCCCATCT
GCATCTCGAGTCGCAGAGACCCCCATAGGTAGTATCTCATCCATGGAAG
TGAATGTGGACACACTGGAGCAAGTAGAACTTATTGACCTTGGGGACCCG
GATGCAGCAGATGTGTTCTTGCCTTGCGAAGATCCTCCACCAACCCCCA
GTCGTCTGGGGTGGACAACCATTTGGAGGAGCTGAGCCTGCCGGTGCCTA
CATCAGACAGGACCAATCTAGGACCTCCTCCTCCTCCTCCTCCGACTCC
TCCACCAACCTGCATAGCCCAAATCCAAGTGATGATGGAGCAGATACGCC
CTTGGCACAGTTCGGATGAAGAGGAGGAAAGGGGTGATGGAGGGGCAGAGC
CTGGAGCCTGCAGCTAGCAGTGGGCCCTGCCTACAGACTGACCACGCTG
GCTATTCTCCACATGAGACCACAGGCCAGCCAGAGCCTGTCCGGAGAAG
ACCAGACTCTTTACTTGCAGTAGCCACAGAGGTGGGAAGGATGGTGGGA
TTGTGTACCTTTCTAAGAATTAACCCCTCCTGCTTTACTGCTAATTTTT
TCTGTGCAACCTCCACCAGTTTTTGGCTTACTCCTGAGATATGATT

```

FIG. 4

FIG. 4 (Fortsetzung)

TGCAAATGAGGAGAGAGAAGATGAGGTTGGACAAGATGCCACTGCTTTTC  
TTAGCACTCTCCCTCCCCTAAACCATCCCGTAGTCTTCTAATACAGTCT  
CTCAGACAAGTGTCTCTAGATGGATGTGAACTCCTTAACTCATCAAGTAA  
GGTGGTACTCAAGCCATGCTGCCTCCTTACATCCTTTTGGAACAGAGCA  
CGGTATAAATAATAAACTAATAATAATATGCC

FIG. 5

rSARG 1 CCAGACTEGAGCGAAGGCTGTGTGCTGGGATGCCAGCTGCCGASGGGCTGCTTACGCC  
mSARG 1 CCAGACCCGGAGCCG--GCCTGTGTGCTGGGAT--CCATC--SCCG--GCCTGCTCGCTCC  
hSARG 1 CCAGGCCCGGAGC--AGGGGGCCCCTCTGTGGGATGCTGGCTGCAS--TEGGGGGCCCCAGGCC

rSARG 61 TTEGCCCCACTACTTTCGTTC--AGCCCCACTTCTGTGGGIGTCTTACTCCATTACCC  
mSARG 56 CACCCCCCCTCCCGCTGTGTCGGGAGCG--ACCCAGG--ATCCA--CGGGCCGGGGCCCTG  
hSARG 61 CAGGTCCCCTCTGTCTTCTCTTTCCA--CTTTCAGCTGTACTTGTCTTTGCTCCTCTACCC

rSARG 120 CCAGGGGCTGACATGGACCCAAATCCGAGCAGCCCTGGAGCGG--CAGCAGCTGCCCTCTC  
mSARG 116 C--AGGGGCTGACATGGACCCAAATCCGAGCAGCCCTGGAGCGCC--CAGCCTCCCGCTC  
hSARG 120 GCAGGAGCTGACATGGACCCAAATCCTGGGGC--SCCCTGGAGGCCAGCAGCTCCGCTT

rSARG 180 AEGGAGCGGCAGAGTTCTTCGAGGACATTTTACAGCCAGAGACAGATTTGTCTTCCCC  
mSARG 175 CGGGAGAGCAGAGTTCTTTTACGAGCATTTTTACAGCCAGAGACAGATTTGTCTTCCCC  
hSARG 180 CGGGAGCGGCAGAAATTTCTTCGAGGACATTTTACAGCCAGAGACAGATTTGTCTTCT

rSARG 240 CTATCCCATCTGCATCTCGAGTCACAAAGACCCCCATAGGTAGCATCTCTCCATGGAA  
mSARG 235 CTGTCCCATCTGCACCTCTGAGTCACAAAGACCCCCATAGGTAGCATCTCTCTATGGAA  
hSARG 240 CTGTCCCATCTGCATCTCGAGTCGAGAGACCCCCATAGGTAGTATCTCATCCATGGAA

rSARG 300 BTGAATGTGGACACACTGGAGCAGGTGGAATTTATTGACCTTGCGGATCAGGATGGAGCA  
mSARG 295 BTGAATGTGGACACACTGGAGCAAGTGAATTTATTGATCTTGCGGATCAGGATGGAGCA  
hSARG 300 BTGAATGTGGACACACTGGAGCAAGTGAACCTTATTGACCTTGCGGACCCGATGAGCA

rSARG 360 BATGTGTTCTTACCTTGTGAGGATTCCTT--CAACTCCCCAGAGCTCTGGAATGGATGAC  
mSARG 355 BATGTGTTCTTGCCTTGTGAGGATTCCTT--GCCAGCTCCCCAGATCTCTGGAATGGATGAC  
hSARG 360 BATGTGTTCTTGCCTTGCAGATCTTCCACCAAC--CCCAGTCCTCTGGGATGGATGAC

rSARG 420 CACCCAGAGGAGCTGAGCCTGCTGGTACCCACGTCAGACAGGACCACATCCCGGACCTCC  
mSARG 415 CATCCAGAGGAGCTGAGCCTGCTGGTACCCACGTCCTTACAGGACCACATCCCGGACCTCC  
hSARG 420 CATTTGAGGAGCTGAGCCTGCCGCTGCT--CATCAGACAGGACCACATCTAEGACCTCC

rSARG 480 TCCTTGTCTCT--SACTCCTCC--ACCTGGCAGTCCAAATCCAAGTGATGGGGGA  
mSARG 475 TCCTTGTCTCT--SACTCCTCC--ACCTGGCAGTCCAAATCCAAGTGATGGGGGA  
hSARG 480 TCCTCCCTCTCTCCSACTCCTCCCAACCTGCTTAGCCCAAATCCAAGTGATGATGGA

rSARG 534 EGAGACACTCCCTTGGCAGATC--TGA--CAGGAGGATGGGGACGCTGGAGGGGCGAG  
mSARG 529 EGAGACACTCCCTTGGCAGATC--TGA--CAGGAGGACGGGGATGACGAGGGGGCAGAG  
hSARG 540 ECAGATACCCCTTGGCAGATCGGATGA--SAGGAGGAAGGGGCTGATGGAGGGGCAGAG

rSARG 591 CCTGGACCTTGCAGCTAGCAGAGCCG--CT--TACAACTGAGCGATCTGGCTGTTCTC  
mSARG 586 CCTGGACCTTGCAGCTAGCAGTGGGCCCTG--TACAGACTGACCAGCCCGCTGTTCTC  
hSARG 600 CCTGGACCTTGCAGCTAGCAGTGGGCCCTGCTGCTACAGACTGACCA--CGCTGGCTATTCTC

rSARG 647 CATGGAGAGGAGACCTTAGGTCCA--CCAGAGC--TCTGGAGAAGACCTGACACTTTACT  
mSARG 643 CATGGAGAGGAGACCT--AGGCCCA--GCAGAGC--CTGGAGAAGACCTGACACTTTCTT  
hSARG 660 CAC--T--T--SAGACCACAGGCCCA--GCAGAGCCTGTGCGSAGAGAAGACCACTCTTTACT

FIG. 5 (Fortsetzung)

rSARG 705 **FACATCAG**-**CACCAAGGGAGGGAGGATGGTGG**-**ATGCTGTGCCTG**----**AGAGTTAGC**  
mSARG 697 **ACTTCAG**-**CACCAAGGGAGGGAGGATGGTGG**-**ATGCTGTGCCTG**----**AGAGTTAGC**  
hSARG 716 **TGCAGTAGG**-**CACCAAGGGT**-**EGGAGGATGGTGGGATTSTGTACCTTTCTAAGAAATTAAC**

rSARG 759 **C**-**TCCC**-**CTTTACTGATAACGCTGTCTGCTGCCACGCCCCAC**-**AGT**----**CTTT**  
mSARG 751 **C**-**TCCCCTGCTTTACC**-**TACGCTATCTGCTGCCACGCCCCAC**-**AGT**----**CTTT**  
hSARG 775 **CTCTCTGCTTTACTGCTAAATTTTTCCTGCTGCAACCCTCCAC**-**AGT**TTTTG**CTTA**

rSARG 811 **-CTTCTGAGGTAGGACTTCCAAGTGAGACTCTCGAAGGTGAGGTGGGACAAGATGCCACT**  
mSARG 803 **TCTTCTGAGGTAGGACTTCCAAGTGAGACTTGGAGGTGAGGTGGGACAAGACCGAGCT**  
hSARG 835 **-CTCTGAGATATGATTTGCAATGAGGAGAGAGAAGATGAGGTGAGACAAGATGCCACT**

rSARG 870 **E**-**TTTTCTTA**-**CTCCCCCTCTGCCCCCAATGATCCTGTAGTCTCCACT**----**AGTCTCCT**  
mSARG 862 **E**-**TTTTCTTA**-**CTCCCCCTCTGCCCCCAATGATCCTGTAGTCTCCACT**----**AGTCTCCT**  
hSARG 894 **CTTCTTCTTA**-**GCACTTTCCTCCCTAATCCATCCCTAGTCTTCTAATCACTCTCTC**

rSARG 926 **AAGCCAGTGTCTCT**-----**AAGGGAAGTTCGAGGAGTCCACTT**-----**TGCAG**  
mSARG 919 **AAGCCAGTGTCTCT**-----**AAGGGGATTTCTGAGGAGTCCACTT**-----**TCCAG**  
hSARG 954 **AGACAAGTGTCTCTAGATGATSTSAACTCCTTAATCTCATCAAGTAAGGTGGTACTCAAG**

rSARG 972 **TTATCCTGCCTCTATAAGTCTTTCTGGGAACAGGATATGGTATAAATAATAA**----**TA**  
mSARG 965 **TTATCCTGCCTCTATAAGTCTTTCTGGGAACAGGATATGGTATAAATAATAA**----**TA**  
hSARG 1014 **CCATGCTGCCTCTATCATCTTTCTTSGAACAGAGCCSGTATAAATAATAAATAA**

rSARG 1028 **ATACTGTACC**  
mSARG 1020 **ATAATATAACC**  
hSARG 1073 **ATAATATGCC**

B

rat 1 **MDPNPRAALERQQLRLRERQKFFEDILQPETEFVFFLSHLHLESQRPPIGSISSEVNVV** § \*

human 1 **MDPNPRAALERQQLRLRERQKFFEDILQPETEFVFFLSHLHLESQRPPIGSISSEVNVV**

rat 61 **TLEQVEFDLADQAGADVLPCEISPPPTPKRSGVDHPEELSILVFTSDRTTSRTSSLS** § §

human 61 **TLEQVELLDLGPAAADVLPCEIPPTPKSSVVDHPEELSILVFTSDRTTSRTSSSS**

rat 121 D--**SSNLRSPNPSDGGDTPLAQSDEEDGDEEGAEFGPDS** # \*

human 121 **SDSSINLHSPNPSDEADTPLAQSDEEERSDGGAEPGACS**

+++++



rSARG-coding	1	ATGGACCCAAATCCACGAGCAGCCCTGGAGCGCAGCAGCTGCCTCTCAGGGAGGGGCAG
mSARG-coding	1	ATGGACCCAAATCCGACAGCAGCCCTGGAGCGCCACAGCTGCCTCCGGGAGAGGECAG
hSARG-coding	1	ATGGACCCAAATCCTCGGGCCCCCTGGAGCGCCAGCAGCTCCGCTCGGGAGGGGCAG
rSARG-coding	61	AAGTTCTTCGAGGACATTTTACAGCCAGAGACAGAGTTTGTTTTCCCCCTATCCCATCTG
mSARG-coding	61	AAGTTCTTCGAGGACATTTTACAGCCAGAGACAGAGTTTGTCTTCCCCCTATCCCATCTG
hSARG-coding	61	AAATTCTTCGAGGACATTTTACAGCCAGAGACAGAGTTTGTCTTTCTCTGTCCCATCTG
rSARG-coding	121	CATCTCGAGTCACAAAGACCCCCATAGGTAGCATCTCCTCGATGGAAGTGAATGTGGAC
mSARG-coding	121	CACCTCGAGTCACAAAGACCCCCATAGGTAGCATCTCCTCGATGGAAGTGAATGTGGAC
hSARG-coding	121	CATCTCGAGTCGCAAGAGACCCCCATAGGTAGTATCTCATCCATGGAAGTGAATGTGGAC
rSARG-coding	181	ACACTGGAGCAGGTGGAATTTATTGACCTTGGGATCAGGATGGAGCAGATGTGTCTTATA
mSARG-coding	181	ACACTGGAGCAAGTGGAGTTTATTGATCTTGGGATCAGGATGGAGCAGATGTGTCTTATG
hSARG-coding	181	ACACTGGAGCAAGTGAACCTTATTGACCTTGGGATCAGGATGGAGCAGATGTGTCTTATG
rSARG-coding	241	CCTTGTGAGGATTCTCCTCCAACTCCCCAGAGCTCTGGAGTGGATGACCACTCAGAGGAG
mSARG-coding	241	CCTTGTGAGGAGTCTCCTCCAGCTCCCCAGATCTCTGGAGTGGATGACCATCCAGAGGAG
hSARG-coding	241	CCTTGTGAGGATCTCCACCACCCCCAGTCTCTGGGTTGGCAACCATTTGAGGAG
rSARG-coding	301	CTGAGCCTGCTGGTACCCACGTCAGACAGGACCACATCCCGGACCTCCTCCTGTCTCTCT
mSARG-coding	301	CTGAGCCTGCTGGTACCCACGTCACAGGACCACATCCCGGACCTCCTCCTGTCTCTCTCT
hSARG-coding	301	CTGAGCCTGCTGGTGCCTACATCAGACAGGACCACATCTAGGACCTCCTCCTCCTCTCTC
rSARG-coding	361	---SACTCCTCCA---ACCTGGCAGTCCAAATCCAAGTGAATGGGGGAGGAGACTCCC
mSARG-coding	361	---SACTCCTCCA---ACCTGGCAGTCCAAATCCAAGTGAATGGGGGAGGAGACTCCC
hSARG-coding	361	TCCSACTCCTCCAACCACTGCATAGCCCAAATCCAAGTGAATGAGGAGCAGATACGCC
rSARG-coding	415	TTGGCACAGTC---TGACGAGGAGGATGGGACCGTGGAGGGGCAGAACCTGGACCTTGC
mSARG-coding	415	TTGGCACAGTC---TGATGAGGAGGACGGGGATGACCGAGGGGCAGAACCTGGACCTTGC
hSARG-coding	421	TTGGCACAGTGGGATGAAAGAGGAGGAAAGGGGTGATGGAGGGGCAGAACCTGGAGCTGTG
rSARG-coding	472	AGCTAG
mSARG-coding	472	AGCTAG
hSARG-coding	481	AGCTAG

FIG. 7

rSARG-coding	1	MDPNPRAALERQQLRLREROKFFEDILOPETEFVFPLSHLHLESQRPPIGSISSMEVNVD
mSARG-coding	1	MDPNPRAALERQQLRLREROKFFEDILOPETEFVFPLSHLHLESQRPPIGSISSMEVNVD
hSARG-coding	1	MDPNPRAALERQQLRLREROKFFEDILOPETEFVFPLSHLHLESQRPPIGSISSMEVNVD
rSARG-coding	61	TLEQVEFIDLADQDGADVFLPCEDSPFTPCRSGVDDHPEELSLLVPTSDRTTSRTSSLSS
mSARG-coding	61	TLEQVEFIDLADQDGADVFLPCEDSSFAPOMSGVDDHPEELSLLVPTSDRTTSRTSSLSS
hSARG-coding	61	TLEQVELIDLGDFAADVFLPCEDSPFTPOSSGVDNHLSELSLFPVPTSDRTTSRTSSSSS
rSARG-coding	121	DS-SNLRSPNPSDGGGDTPLAQSDEED--EDCGAEPGPCS
mSARG-coding	121	DS-SNLRSPNPSDGGGDTPLAQSDEED--EDCGAEPGPCS
hSARG-coding	121	SSSTNLHSPNPSDGGGDTPLAQSDEEEERED--CGAEPGACS

FIG. 8

FIG. 9A




FIG. 9B




FIG. 9C







FIG. 9D



E



F







FIG. 10

FIG.11






FIG. 12





FIG. 13





FIG. 14

t→c point mutation in a familial multiple sclerosis patient at nucleotide 67 of coding sequence. Substitution of phenylalanine (F) for leucine (L) at amino acid 23.




Wild type 1	MDPNPRAALERQQLRLRERQKFFEDILQPETEFVFPPLSHLHLESQRPPIGSISSEVNVD	60
Mutation 1	MDPNPRAALERQQLRLRERQKFLLEDILQPETEFVFPPLSHLHLESQRPPIGSISSEVNVD	60
Wild type 61	TLEQVELIDLGDPAADVFLPCEDPPPTPQSSGVDNHLEELSLFVPTSDRRTTSRTSSSSS	120
Mutation 61	TLEQVELIDLGGPDAADVFLPCEDPPPTPQSSGVDNHLEELSLFVPTSDRRTTSRTSSSSS	119
Wild type 121	SDSSTNLHSPNPSDDGADTPLAQSDDEEERGDGGAEPGACS	161
Mutation 120	SDSSTNLHSPNPSDDGADTPLAQSDDEEERGDGGAEPGACS	160

FIG. 15

c→t point mutation in a familial multiple sclerosis patient at nucleotide 359 of coding sequence. Substitution of Phenylalanine (F) for serine (S) at amino acid 120

115	116	117	118	119	120	121
T	S	S	S	S	F	S

**A C C T C C T C C T C C C T T C T C C G**




Wild type 1	MDPNPRAALERQQLRLRERQKFFEDILQPETEFVFPPLSHLHLESQRPPIGSISSMEVNVD	60
Mutattion 1	MDPNPRAALERQQLRLRERQKFFEDILQPETEFVFPPLSHLHLESQRPPIGSISSMEVNVD	60
Wild type 61	TLEQVELIDLGDPAADVFLPCEDPPPTPQSSGVDNHLEELSLPVPTSDRRTSRTSSSSS	120
Mutation 61	TLEQVELIDLGDPAADVFLPCEDPPPTPQSSGVDNHLEELSLPVPTSDRRTSRTSSSSF	119
Wild type 121	SDSSTNLHSPNPSDDGADTPLAQSDDEEEERG DGG AEPGACS	161
Mutation 120	SDSSTNLHSPNPSDDGADTPLAQSDDEEEERG DGG AEPGACS	160

FIG. 16

a→g point mutation in a familial multiple sclerosis patient at nucleotide 89 of coding sequence. Substitution of glycine (G) for glutamic acid (E) at amino acid 30.

29 30 31  
P G T

A G C C C G G G A C C G A




Wild type 1	MDPNPRAALERQQLRLRERQKFFEDILQPETEFVFPPLSHLHLESQRPPIGSISMEVNVD	60
Mutation 1	MDPNPRAALERQQLRLRERQKFFLEDILQPGTEFVFPPLSHLHLESQRPPIGSISMEVNVD	60
Wild type 61	TLEQVELIDLGDPAADVFLPCEDPPPTPQSSGVDNHLEELSLPVPTSDRTTSRTSSSSS	120
Mutation 61	TLEQVELIDLGGPDAADVFLPCEDPPPTPQSSGVDNHLEELSLPVPTSDRTTSRTSSSSS	119
Wild type 121	SDSSTNLHSPNPSDDGADTPLAQSDDEEERGDGGAEPGACS	161
Mutation 120	SDSSTNLHSPNPSDDGADTPLAQSDDEEERGDGGAEPGACS	160

FIG. 17

Deletion of codon in familial multiple sclerosis patient. Loss of serine residue

60	61	62	63	64	65	66	67
R	T	S	S	S	S	S	D

C T A G G A C C T C C T C C T C C T C C G A C



Wild type 1	MDPNPRAALERQQLRLRERQKFFEDILQPETEFVFPPLSHLHLESQRPPIGSISSMEVNVD	60
Mutattion 1	MDPNPRAALERQQLRLRERQKFFEDILQPETEFVFPPLSHLHLESQRPPIGSISSMEVNVD	60
Wild type 61	TLEQVELIDLGDPDAADVFLPCEDPPPTPQSSGVDNHLEELSLPVPTSDRRTTSRTSSSSS	120
Mutation 61	TLEQVELIDLGDPDAADVFLPCEDPPPTPQSSGVDNHLEELSLPVPTSDRRTTSRT-SSSS	119
Wild type 121	SDSSTNLHSPNPSDDGADTPLAQSDDEEEERGDDGGAEPGACS	161
Mutation 120	SDSSTNLHSPNPSDDGADTPLAQSDDEEEERGDDGGAEPGACS	160

FIG. 18

FIG. 19

## SARG INTRON/EXON STRUCTURE

Transcription start site initiator consensus YGCARR is underlined  
 Donor (GU) and acceptor (AG) splice sites are underlined in italics

Exons are in bold type

Coding exon sequences are in italics

## EXON 1

*CCAGGCCGGAGCCAGGGGCCCACTGTTGGGATGCTGGCTGCAGTGGGGCGCCCAAGCCCAGGT*  
*CCCCTCTGTCTTCTCTTTGACTTTGCAGCTGTACTTGTTTGCTCCTCTACCCGCAGGAGCTGA*

C

+1

ATGGACCCAAATCCTCGGGCCGCCCTGGAGCGCCAGCAGCTCCGCCTTCGGGAGCGGCAAAAATT  
 CTTGAGGACATTTTACAGCCAGAGACAGAGTTTGTCTTTCTCTGTCCCATCTGCATCTCGAGT  
 CGCAGAGAC

+139

## INTRON 1

*GTAAGTCCCAAGTCTGAGAAGAGGGACTGGGGTAGGGTAGGGA*  
*GGATGTCTGTGGGTCTGAATCTTGTGGCACTCTCTCCCCTCTGGTTTT*  
*CTTGGCCCTCTATGCTTCTAACTTGGGACCTGACATGTAACTCTCACTGT*  
*CCTGGTGTGCAGCTTGGGTCTCTGACTTGCCCACTTCTTGATCCGCAG*

## EXON 2

+139

CCCCATAGGTAGTATCTCATCCATGGAAGTGAATGTGGACACACTGGAGCAAGTAGAACTTATT  
 GACCTTGGGGACCCGGATGCAGCAGATGTGTTCTTGCCTTGCGAAGATCCTCCACCAACCCCCCA  
 GTCGTCTG

+276

## INTRON 2

*GATGCCCTCTGCTTTGGGGACTTCAGTGCCAGTCAGCCAGAGCCGGATGTCAGGCTCTGA*  
*AACGAGGCTACAAGGCTGGGCTGGGGAAGTACACAAGTAAGGGCTGGAAG*  
*TGGGTGTTTCTACCAATGAAACAGCTGCCTGTTCTGATTTTAGGGAAGTT*  
*GACCCTGAGGGAGAACTGGGTACACATCTCTAATCCAAAATTCTGGGAA*  
*CGGTCAATCTCTTTAATTTTACATTTGTTATATTAATAATAATTAGTC*  
*ACTATAATTAAATAATGTAATAATTTTATATTTGGCAACTTAA*  
*GTAGTTTTAGTCATTATAATGATATTAATATGTATTGAGTACTTTAGTAG*  
*GTTCCAATACTGTACTAAAGTACTTTACATATATTATCTCAATCCTTACA*

FIG. 19 (Fortsetzung)

ACGTCCTGTCAGGGTAGGTGATATAATCTCTATTTTATAAGCAGGAAATT  
 AGGCTCAGAGAAGTTAAGTCACATTGTAGCCAGAAGGTAGATAAACTGGA  
 ATTCATGTCCTGTCTGACTCCAAAGCCCATATGCTTAACTTGTAAGATAGA  
 TATTCTTTTAATTA AAACTGCTACTATTTATTGATGGCTTACTATGCCAG  
 ACATTTTATAAGCATTCTTAGGTTTTATTCCCAAACCCCTTTGGGGATGT  
 AGGTATCCCTTTTTATTTTGCAGAGGAGGAACAGAGTCCTTGAAAGGGAAA  
 GTGACTTGCTCAAAGCCACTCAGCAGCAATAAGTGATGTAGGTGGAACCT  
 GAACTCTTGCCATTCAATTGACCTGACTGTAGATCCCAGACATGGTGTAAT  
 GACGTGGAAGGAGCTGGCAGTCAGGAGATGGTGATCTTAATCCTGGCTCT  
 TTGCTGGATGGCAAAGTCACCTTGGACAAGTCTCTGCCCCACTGTGGAC  
 TTTAGTTACTCCTGGCCAGATAATCTTTAAGAGTTCTCTGAAGCCCTGTT  
 TGTGGCCTGACCAGCTTTTCTCTCTGGGCAG

EXON 3

+276

GGGTGGACAACCATTTGGAGGAGCTGAGCCTGCCGGTGCCTACATCAGACAGGACCACATCTAGG  
 ACCTCCTCCTCCTCCTCCTCCGACTCCTCCACCAACCTGCATAGCCCAAATCCAAGTGATGATGG  
 AGCAGATACGCCCTTGGCACAGTCGGATGAAGAGGAGGAAAGGGGTGATGGAGGGGCAGAGCCTG  
 GAGCCTGCAGCTAG

+485

CAGTGGGCCCCCTGCCTACAGACTGACCACGCTGGCTATTTCTCCACATGAGACCACAGGCCAGCC  
 AGAGCCTGTCCGGAGAAGACCAGACTCTTTACTTGCAGTAGGCACCAGAGGTGGAAGGATGGTG  
 GGATTGTGTACCTTTCTAAGAATTAACCCT  
 CTCCTGCTTTACTGCTAATTTTTCTGCTGCAACCTCCCACCAGTTTT  
 TGGCTTACTCCTGAGATATGATTTGCAAATGAGGAGAGAGAAGATGAGGT  
 TGGACAAGATGCCACTGCTTTCTTAGCACCTTCCCTCCCCTAAACCAT  
 CCCGTAGTCTTCTAATACAGTCTCTCAGACAAGTGTCTCTAGATGGATGT  
 GAACTCCTTAACTCATCAAGTAAGGTGGTACTCAAGCCATGCTGCCTCCT  
 TACATCCTTTTTGGAACAGAGCACGGTATAAATAATAAACTAATAATAAT  
 ATGCC

## REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

## Non-patent literature cited in the description

- **Ed Harlow.** Antibodies: A laboratory manual. Cold Spring Harbor Laboratory [0028]
- **David Lane.** Imperial Cancer Research Fund Laboratories. 1988 [0028]
- **Li ; Cohen.** *Cell*, 1996, vol. 85, 319-329 [0034]
- **Keown et al.** *Methods in Enzymology*, 1990, vol. 185, 527-537 [0039]
- **Bauer et al.** *NAR*, 1993, vol. 21, 4272-4280 [0068]
- **Bench et al.** *Oncogene*, 2000, vol. 19, 3902-3913 [0068]
- **Chataway et al.** *Brain*, 1998, vol. 121, 1869-1887 [0068]
- **Corset et al.** *Nature*, 2000, vol. 407, 747-750 [0068]
- **Deloukas et al.** *Nature*, 2001, vol. 414, 865-871 [0068]
- **Ebers et al.** *Nature*, vol. 377, 150-151 [0068]
- Cell death. **Fraker et al.** *Methods in Cell Biology*. Academic press, vol. 46, 57-76 [0068]
- **Fu et al.** *J. Biol.Chem.*, 1999, vol. 274, 7264-7271 [0068]
- **Galiegue et al.** *J.Biol.Chem.*, 1999, vol. 274, 2938-2952 [0068]
- **Gu et al.** *Cell*, 1993, vol. 73, 1155-1164 [0068]
- **Haines et al.** *Hum.Mol.Genet.*, 1998, vol. 7, 1229-1234 [0068]
- **Hashimoto et al.** *Exp. Cell Res.*, 1989, vol. 184, 351-359 [0068]
- **Jacobson et al.** *Nature Genetics*, 2000, vol. 26, 495-499 [0068]
- **Johnson et al.** *Gene Probes 2, A Practical Approach*. Oxford University Press, 1995, 313-327 [0068]
- **Kaufman.** *The Atlas of Mouse Development*. Academic Press, 1992 [0068]
- **Liang et al.** *Science*, 1992, vol. 257, 967-971 [0068]
- **Liang et al.** *NAR*, 1993, vol. 21, 3269-3275 [0068]
- **Liang et al.** *Current opinions in Immunology*, 1995, vol. 7, 274-280 [0068]
- **Lucas et al.** *FASEB J.*, 1999, vol. 13, 263-272 [0068]
- **Olson et al.** *Cell*, 1996, vol. 5, 1-4 [0068]
- **Ono et al.** *J. Biol.Chem.*, 2000, vol. 275, 31145-31154 [0068]
- **Papaioannou et al.** *Gene Targeting - A Practical Approach*. 2000 [0068]
- **Patapoutian et al.** *Curr. Opin. Neurobiol.*, 2001, vol. 11, 272-280 [0068]
- **Pham et al.** *PNAS*, 1996, vol. 93, 13090-13095 [0068]
- **Rechsteiner et al.** *TIBS*, 1996, vol. 21, 267-271 [0068]
- **Rossi et al.** *EMBO j.*, 2001, vol. 20, 2844-2856 [0068]
- **Sabath et al.** *Biotechniques*, 2000, vol. 5, 966-972 [0068]
- **Sadovnick et al.** *Clin. Genet.*, 2000, vol. 58, 431-435 [0068]
- **Sambrock et al.** *Molecular cloning a laboratory manual*. 1989 [0068]
- **Sawcer et al.** *Curr. Opin. Immunol.*, 1998, vol. 10, 697-703 [0068]
- **Verma et al.** *J. Biol.Chem.*, 2001, vol. 276, 4671-4676 [0068]
- **Wattel et al.** *Leuk. Res.*, 1993, vol. 17, 921-926 [0068]
- **Weinshenker et al.** *Neurology*, 2000, vol. 54, 542-544 [0068]
- **White et al.** *PNAS*, 2000, vol. 97, 13967-13972 [0068]
- **Zipp.** *Cell Tissue Res.*, 2000, vol. 301, 163-171 [0068]

专利名称(译)	一种诊断患有多发性硬化症的人的方法		
公开(公告)号	<a href="#">EP1407269B1</a>	公开(公告)日	2010-10-20
申请号	EP2002754716	申请日	2002-06-20
[标]申请(专利权)人(译)	严实BURKHARD 卢卡斯特里沃		
申请(专利权)人(译)	严实, BURKHARD LUCAS, TREVOR		
当前申请(专利权)人(译)	严实, BURKHARD LUCAS, TREVOR		
[标]发明人	JANSEN BURKHARD LUCAS TREVOR		
发明人	JANSEN, BURKHARD LUCAS, TREVOR		
IPC分类号	G01N33/564 A01K67/027 A61K38/00 A61K38/17 A61P25/00 A61P35/00 A61P35/02 C07K1/22 C07K14/47 C07K16/18 C12N15/09 C12P21/08 C12Q1/68 C12Q1/6883 G01N33/48 G01N33/53 G01N33/566 G01N33/574 G01N33/577 G01N33/68 G01N37/00		
CPC分类号	A01K2217/05 A61K38/1709 A61P25/00 A61P35/00 A61P35/02 C07K1/22 C07K14/47 C07K14/4713 C07K16/18 C12Q1/6883 C12Q2600/156 G01N33/564 G01N33/57484 G01N33/6893 G01N33/6896 G01N2800/285		
优先权	60/299765 2001-06-22 US		
其他公开文献	EP1407269A2		
外部链接	<a href="#">Espacenet</a>		

摘要(译)

描述了一种诊断患有多发性硬化症 ( MS ) 或有发生MS风险的人的方法, 包括以下步骤: - 从所述人提供体液或组织样品, 所述样品含有至少一种野生体类型SCF-凋亡 - 反应基因 - ( wt-SARG-1- ) 蛋白和编码wt-SARG-1的核酸, 如果取自没有MS的人或有获得MS的风险; - 检测所述样品中wt-SARG-1-蛋白或编码wt-SARG-1的核酸的存在并诊断MS或获得MS的风险, 如果wt-SARG-1-蛋白或编码wt-SARG-的核酸所述样品中不存在1。

MDIPDAALRQRRLRERQKFEEDLQPEETVTFPLSHLHRSQPPPGSTSSMHNVDLIR

QVLLIDLCQPDAAVPLPEEDPPTPGSSGTDHILRELSHPVPSDRPTSSSSSSSSSTLHSPN

PSDGLDTPLAQSEEEERGGGGRPGAS